<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001798.pub3" GROUP_ID="NEUROMUSC" ID="947599090817520253" MERGED_FROM="" MODIFIED="2017-03-17 11:23:17 +0000" MODIFIED_BY="Ruth Brassington" REVIEW_NO="012" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2017-03-17 11:23:16 +0000" MODIFIED_BY="Ruth Brassington">
<TITLE>Plasma exchange for Guillain-Barré syndrome</TITLE>
<CONTACT MODIFIED="2017-03-17 11:23:16 +0000" MODIFIED_BY="Ruth Brassington"><PERSON ID="5686" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Djillali</FIRST_NAME><LAST_NAME>Annane</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>djillali.annane@rpc.ap-hop-paris.fr</EMAIL_1><ADDRESS><DEPARTMENT>Critical Care Department</DEPARTMENT><ORGANISATION>Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris</ORGANISATION><ADDRESS_1>104. Boulevard Raymond Poincaré</ADDRESS_1><CITY>Garches</CITY><ZIP>92380</ZIP><REGION>Ile de France</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 47 10 77 86</PHONE_1><PHONE_2>+33 1 47 10 77 87</PHONE_2><FAX_1>+33 1 47 10 77 83</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-03-17 11:23:16 +0000" MODIFIED_BY="Ruth Brassington"><PERSON ID="15371" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Sylvie</FIRST_NAME><LAST_NAME>Chevret</LAST_NAME><POSITION>Professor of Medicine</POSITION><EMAIL_1>sylvie.chevret@paris7.jussieu.fr</EMAIL_1><ADDRESS><DEPARTMENT>Departement de Biostatistique et Informatique Médicale</DEPARTMENT><ORGANISATION>Hôpital Saint Louis</ORGANISATION><ADDRESS_1>1 Avenue Claude Vellefaux</ADDRESS_1><CITY>75475 Paris</CITY><ZIP>Cedex 10</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 42 49 97 42</PHONE_1><PHONE_2>+33 1 42 49 97 45</PHONE_2></ADDRESS></PERSON><PERSON ID="7655" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>AC</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><SUFFIX>MD FRCP FMedSci</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>rhughes11@btinternet.com</EMAIL_1><EMAIL_2>richard.hughes@ucl.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7676 2060</PHONE_1><FAX_1>+44 20 7829 8725</FAX_1></ADDRESS></PERSON><PERSON ID="5686" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Djillali</FIRST_NAME><LAST_NAME>Annane</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>djillali.annane@rpc.ap-hop-paris.fr</EMAIL_1><ADDRESS><DEPARTMENT>Critical Care Department</DEPARTMENT><ORGANISATION>Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris</ORGANISATION><ADDRESS_1>104. Boulevard Raymond Poincaré</ADDRESS_1><CITY>Garches</CITY><ZIP>92380</ZIP><REGION>Ile de France</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 47 10 77 86</PHONE_1><PHONE_2>+33 1 47 10 77 87</PHONE_2><FAX_1>+33 1 47 10 77 83</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-02-10 12:48:58 +0000" MODIFIED_BY="Ruth Brassington">
<UP_TO_DATE>
<DATE DAY="18" MONTH="1" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="1" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="1" YEAR="2020"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-03-17 11:03:45 +0000" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-03-17 11:03:45 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="17" MONTH="3" YEAR="2017"/>
<DESCRIPTION>
<P>Correction to 'Summary of findings' table outcome 'Walking with aid at 4 weeks' and removal of moderate risk from whole table.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-03-17 11:00:27 +0000" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-03-17 11:00:23 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="20" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>New search from 18 January 2016 incorporated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-03-17 11:00:27 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="20" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>No new trials</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-09-21 22:00:13 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="30" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Updated searches were run to 14 June 2011. There were no new randomised controlled trials</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-09-21 22:00:19 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="15" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P> 'Risk of bias' tables and 'Summary of findings' tables have been incorporated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-07-13 11:04:53 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="14" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Updated searches were run to January 2008. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-07-13 11:01:44 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="15" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-04-15 17:02:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>We updated the searches in 2006. We searched the Cochrane Neuromuscular Disease Group specialised register (March 2006), MEDLINE (to May 2006) and EMBASE (to May 2006). No new relevant references were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="12" MONTH="12" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Hopital Raymond Poincaré, Garches</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Guy's, King's and St Thomas' School of Medicine, King's College, London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-03-17 11:03:14 +0000" MODIFIED_BY="Ruth Brassington">
<SUMMARY MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2008-04-15 17:08:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Include quality statement&lt;/p&gt;&lt;p&gt;Expand results slightly?&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-04-15 17:08:48 +0100" NOTES_MODIFIED_BY="[Empty name]">Plasma exchange for Guillain-Barré syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2017-01-23 16:56:48 +0000" MODIFIED_BY="Ruth Brassington">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence about the effect of plasma exchange in people with Guillain-Barré syndrome (GBS).</P>
<P>
<B>Background</B>
</P>
<P>GBS is a rare, serious disease in which the peripheral nerves (nerves outside the central nervous system) become inflamed. The condition causes paralysis and sensory disturbance. Many people who develop GBS have had a recent chest or intestinal infection that may cause an allergic attack on the nerves. Antibodies against the infection also target the nerves and cause GBS. Plasma exchange removes soluble factors including antibodies from the blood and is used as treatment. Plasma exchange replaces the person's own plasma with an artificial plasma substitute, usually an albumin solution.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We carried out a wide search of medical databases for trials in which participants were randomly assigned to plasma exchange or no treatment except supportive care. We found six trials, which included 649 participants in total. All six trials compared plasma exchange with supportive treatment. All were at low risk of bias, except that participants and their carers were aware of the treatment given (they were not blinded). Two additional studies compared different numbers of plasma exchange and could not be included in the analysis but are discussed.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>Plasma exchange speeded improvement from GBS. It did not cause harm apart from being followed by a probable slight increase in risk of relapse. Despite this, plasma exchange probably increases the chance of complete muscle strength recovery after one year. No new trials have been done since the first publication of this review in 2001. However trials have been done comparing plasma exchange with intravenous infusion of human immune globulin (the antibody portion of plasma). These trials are included in another Cochrane review and show the effects of the two treatments are similar.</P>
<P>The evidence is up to date to 18 January 2016.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<ABS_BACKGROUND MODIFIED="2017-01-18 10:44:23 +0000" MODIFIED_BY="Ruth Brassington">
<P>Guillain-Barré syndrome (GBS) is an acute paralysing disease caused by peripheral nerve inflammation. This is an update of a review first published in 2001 and last updated in 2012.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-01-09 15:58:05 +0000" MODIFIED_BY="Ruth Brassington">
<P>To assess the effects of plasma exchange for treating GBS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<P>On 18 January 2016 we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, and Embase. We also searched clinical trials registries.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-01-18 10:45:20 +0000" MODIFIED_BY="Ruth Brassington">
<P>Randomised and quasi-randomised trials of plasma exchange versus sham exchange or supportive treatment, or comparing different regimens or techniques of plasma exchange.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-01-09 15:59:32 +0000" MODIFIED_BY="Ruth Brassington">
<P>We followed standard Cochrane methodology.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-01-23 16:56:38 +0000" MODIFIED_BY="Ruth Brassington">
<P>In the first version of this review there were six eligible trials concerning 649 participants comparing plasma exchange with supportive treatment. No new eligible trials have been identified in subsequent updates. Two other studies compared different numbers of plasma exchanges. Overall the included trials had a moderate risk of bias (in general, the studies were at low risk but all had a high risk of bias from lack of blinding).</P>
<P>In one trial with 220 severely affected participants, the median time to recover walking with aid was significantly shorter with plasma exchange (30 days) than without plasma exchange (44 days). In another trial with 91 mildly affected participants, the median time to onset of motor recovery was significantly shorter with plasma exchange (six days) than without plasma exchange (10 days). After four weeks, moderate-quality evidence from the combined data of three trials accounting for a total of 349 patients showed that plasma exchange significantly increased the proportion of patients who recovered the ability to walk with assistance (risk ratio (RR) 1.60, 95% confidence interval (CI) 1.19 to 2.15).</P>
<P>In five trials with 623 participants in total, moderate-quality evidence showed that the RR for improvement by one or more disability grades after four weeks was 1.64 (95% CI 1.37 to 1.96) times greater with plasma exchange. Participants treated with plasma exchange also fared better, according to moderate-quality evidence, in time to recover walking without aid (three trials with 349 participants; RR 1.72, 95% CI 1.06 to 2.79) and requirement for artificial ventilation (five trials with 623 participants; RR 0.53, 95% CI 0.39 to 0.74). More participants had relapses by the end of follow-up in the plasma exchange group than in the control group (six trials with 649 participants; RR 2.89, 95% CI 1.05 to 7.93; moderate-quality evidence). Despite this, according to moderate-quality evidence, the likelihood of full muscle strength recovery at one year was greater with plasma exchange than without plasma exchange (five trials with 404 participants; RR 1.24, 95% CI 1.07 to 1.45), and the likelihood of severe motor sequelae was less (six trials with 649 participants; RR 0.65, 95% CI 0.44 to 0.96). High-quality evidence from six trials with 649 participants could not confirm or refute a lower risk of death following plasma exchange compared to control (RR 0.86, 95% CI 0.45 to 1.65).</P>
<P>Three trials (N = 556) provided details of serious adverse events during the hospital stay; combined analyses found no increase in serious infectious events compared to the control group (RR 0.91, 95% CI 0.73 to 1.13), nor were there clear differences in blood pressure instability, cardiac arrhythmias or pulmonary emboli.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-01-23 16:56:42 +0000" MODIFIED_BY="Ruth Brassington">
<P>Moderate-quality evidence shows significantly more improvement with plasma exchange than with supportive care alone in adults with Guillain-Barré syndrome, without a significant increase in serious adverse events. According to moderate-quality evidence, there was a small but significant increase in the risk of relapse during the first six to 12 months after onset in people treated with plasma exchange compared with those who were not treated. Despite this, after one year, full recovery of muscle strength was more likely and severe residual weakness less likely with plasma exchange.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-03-17 11:03:14 +0000" MODIFIED_BY="Ruth Brassington">
<BACKGROUND MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<CONDITION MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<P>Guillain-Barré syndrome (GBS) is an acute, usually symmetrical, and typically ascending, paralysing disorder caused by inflammation of the peripheral nerves. GBS usually occurs as a random and rare event in the general population, at a rate of about 0.5 to 2 cases per 100,000 persons per year. About half the cases follow within a few days to a few weeks of an infection. Some infectious agents implicated as triggering GBS cause gastroenteritis with diarrhoea. Others cause respiratory infections. Many lines of evidence support the likelihood that GBS is an autoimmune disorder, with the person's antibodies targeted to attack various components of peripheral nerve myelin or the axon. In the commonest form of the disease in Europe and North America, acute inflammatory demyelinating polyradiculoneuropathy, the myelin sheath is the target of the immune response but the precise antigen involved remains unknown. In acute motor axonal neuropathy, the commonest form of the disease in parts of Southeast Asia and Central America, the immune response targets the axon at the nodes of Ranvier. In early studies of acute inflammatory demyelinating polyradiculoneuropathy, demyelinating serum factors were identified. Serum of people with GBS was shown to produce electrophysiological and histological signs of acute demyelination in myelinated tissue cultures and following intraneural injection (<LINK REF="REF-Cook-1971" TYPE="REFERENCE">Cook 1971</LINK>; <LINK REF="REF-Harrison-1984" TYPE="REFERENCE">Harrison 1984</LINK>; <LINK REF="REF-Sumner-1982" TYPE="REFERENCE">Sumner 1982</LINK>). There was a positive correlation between the demyelinating activity and severity of neurological disease (<LINK REF="REF-Metral-1989" TYPE="REFERENCE">Metral 1989</LINK>). However, the precise mechanism and target antigen have not yet been identified (<LINK REF="REF-Willison-2016" TYPE="REFERENCE">Willison 2016</LINK>). In acute motor axonal neuropathy there is strong evidence that antibodies to gangliosides on the axolemma at the nodes of Ranvier are responsible (<LINK REF="REF-Yuki-2012" TYPE="REFERENCE">Yuki 2012</LINK>; <LINK REF="REF-Willison-2016" TYPE="REFERENCE">Willison 2016</LINK>). Many, but not all, people with GBS recover over months to two or more years. Treatments have been sought to: (1) accelerate recovery, (2) decrease complications during the acute illness, and (3) decrease the amount of long-term residual neurological deficit. Plasma exchange was introduced for the treatment of GBS in the expectation of removing circulating antibodies or other factors responsible for the nerve damage.</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<P>Therapeutic plasma exchange has been used in medical conditions for many years, either to remove toxic factors or to replace a missing factor (<LINK REF="REF-Shumak-1984" TYPE="REFERENCE">Shumak 1984</LINK>). The technique consists of separating plasma from cells using membrane filtration or centrifugation. Cells are re-infused into the person with GBS at the same time as plasma is being removed. Albumin diluted with gelatin or fresh frozen plasma is used to maintain volume and osmotic equilibrium. Plasma exchange has significant constraints and a morbidity associated with it. Specific devices and teams trained in the use of extracorporeal circulation are needed. Clinical efficacy depends on many factors including volume of plasma exchanged, number and frequency of sessions, nature of the replacement solution, and the separating technique.</P>
</INTERVENTION>
<THEORY MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<P>The first uses of plasma exchange in treatment of GBS were reported between 1978 and 1981, with small uncontrolled series claiming clinical benefit (<LINK REF="REF-Brettle-1978" TYPE="REFERENCE">Brettle 1978</LINK>; <LINK REF="REF-Mark-1980" TYPE="REFERENCE">Mark 1980</LINK>; <LINK REF="REF-Ropper-1980" TYPE="REFERENCE">Ropper 1980</LINK>; <LINK REF="REF-Schooneman-1981" TYPE="REFERENCE">Schooneman 1981</LINK>; <LINK REF="REF-Valbonesi-1981" TYPE="REFERENCE">Valbonesi 1981</LINK>). Since these first reports, six RCTs have been conducted and published comparing plasma exchange with supportive treatment alone (<LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>; <LINK REF="STD-Greenwood-1984" TYPE="STUDY">Greenwood 1984</LINK>; <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). Four RCTs showed short-term benefit (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>), of which one also showed sustained benefit after 12 months (<LINK REF="REF-Rapha_x00eb_l-1992" TYPE="REFERENCE">Raphaël 1992</LINK>). Another RCT showed the efficacy of plasma exchange in mild forms of the disease (<LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). A narrative review (<LINK REF="REF-Rapha_x00eb_l-1996" TYPE="REFERENCE">Raphaël 1996</LINK>) and one consensus conference (<LINK REF="REF-Consensus-1986" TYPE="REFERENCE">Consensus 1986</LINK>) recommended the use of plasma exchange in severe GBS (i.e. those who are confined to a chair or to a bed, or mechanically ventilated).</P>
<P>The use of cerebrospinal fluid (CSF) filtration was considered as an alternative to plasma exchange because of the identification of factors that block nerve conduction in the spinal fluid in GBS and other inflammatory disorders (<LINK REF="STD-Wollinsky-2001" TYPE="STUDY">Wollinsky 2001</LINK>). One such factor is a pentapeptide QYNAD (Gln-Tyr-Asn-Ala-Asp). A single RCT has compared CSF filtration with plasma exchange (<LINK REF="STD-Wollinsky-2001" TYPE="STUDY">Wollinsky 2001</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-01-09 16:04:22 +0000" MODIFIED_BY="Ruth Brassington">
<P>The determination of the size of any beneficial effect of plasma exchange requires a systematic review. The primary aim of the present review was to search systematically for, and combine all evidence from, randomised trials relating to the effects of plasma exchange in GBS in order to supply the best evidence currently available on which to base recommendations for clinical practice and further research. This review intended to take into account known prognostic factors including, age, severity of disability (<LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>), presence or absence of sensory deficit, previous history of diarrhoea (<LINK REF="REF-PSGBS-Group-1997" TYPE="REFERENCE">PSGBS Group 1997</LINK>; <LINK REF="REF-Visser-1999" TYPE="REFERENCE">Visser 1999</LINK>), reduced distal motor amplitude on electrodiagnostic testing, and time from onset of neuropathy to the start of treatment (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="REF-McKhann-1988" TYPE="REFERENCE">McKhann 1988</LINK>). This is an update of a review first published in 2001 and last updated in 2012.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-01-09 16:04:23 +0000" MODIFIED_BY="Ruth Brassington">
<P>To assess the effects of plasma exchange for treating GBS.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<SELECTION_CRITERIA MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<CRIT_STUDIES MODIFIED="2012-01-11 05:02:19 +0000" MODIFIED_BY="Ruth Brassington">
<P>All randomised or quasi-randomised clinical trials. We made a particular effort to include unpublished randomised studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<P>We included children and adults with GBS of all degrees of severity. GBS was defined according to internationally accepted diagnostic criteria as acute polyradiculoneuropathy causing progressive weakness of two or more limbs, an onset phase of not more than four weeks, reduced or absent tendon reflexes and lacking alternative causes (<LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>). Studies that did not conform exactly to these criteria were included provided that the authors regarded GBS or one of its synonyms, such as acute idiopathic neuropathy or acute inflammatory demyelinating polyradiculoneuropathy, as the preferred diagnosis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-01-23 16:56:55 +0000" MODIFIED_BY="Ruth Brassington">
<P>We only considered trials evaluating plasma exchange alone. We considered trials comparing plasma exchange with supportive care or sham exchange, or comparing different modalities of plasma exchange (doses, type of fluid replacement, or separation techniques). We analysed the influence of plasma volume exchanged, number of plasma exchanges, and types of replacement solution.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-01-23 16:56:55 +0000" MODIFIED_BY="Ruth Brassington">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-01-23 16:56:55 +0000" MODIFIED_BY="Ruth Brassington">
<P>The main criterion was time after randomisation to recover walking with aid. In participants who did not lose the ability to walk, we used the time to onset of motor recovery as a main end point, and defined it as the time required to recover at least two functional items or one item with an improvement in cranial nerve function or trunk or respiratory muscle involvement (<LINK REF="REF-Rapha_x00eb_l-1992" TYPE="REFERENCE">Raphaël 1992</LINK>).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-01-20 11:31:30 +0000" MODIFIED_BY="Ruth Brassington">
<OL>
<LI>We found that the outcome measure 'change in disability grade (<LINK REF="REF-Hughes-1978" TYPE="REFERENCE">Hughes 1978</LINK>) four weeks after randomisation' was reported as the primary end point in many of the trials included in this meta-analysis, and available in all trials. Thus, this outcome measure was upgraded in the list of secondary end points for this review.</LI>
<LI>Time to recovery of walking without aid.</LI>
<LI>Dependency on a ventilator.</LI>
<LI>Time after randomisation to weaning from the ventilator.</LI>
<LI>Full muscle strength recovery at one year.</LI>
<LI>Deaths at one year.</LI>
<LI>Death or severe sequelae at one year, defined by the loss of at least one of the following six functions: ability to walk, with or without aid, climb stairs, dress, cut meat, or write (<LINK REF="REF-Rapha_x00eb_l-1992" TYPE="REFERENCE">Raphaël 1992</LINK>).</LI>
<LI>Relapses at one year. Relapse is defined by deterioration in strength causing an increase in disability grade (<LINK REF="REF-Hughes-1978" TYPE="REFERENCE">Hughes 1978</LINK>), or loss of two or more items of the functional muscle strength scale (<LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>), for at least one week.</LI>
<LI>Complications:</LI>
<OL>
<LI>development of new infection treated with antibiotics;</LI>
<LI>development of hypertension requiring drug treatment;</LI>
<LI>other autonomic disorders: unexplained drop in systolic blood pressure by more than 20 mm Hg, unexplained drop in heart rate by more than 20 beats per minute, or unexplained rise in heart rate above 120 beats per minute.</LI>
</OL>
<LI>Discontinuation of plasma exchange (owing to poor haemodynamic tolerance).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-01-23 16:57:18 +0000" MODIFIED_BY="Ruth Brassington">
<ELECTRONIC_SEARCHES MODIFIED="2017-01-23 16:57:18 +0000" MODIFIED_BY="Ruth Brassington">
<P>We searched the following databases without language restriction: </P>
<UL>
<LI>Cochrane Neuromuscular Specialised Register (searched 18 January 2016);</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL; searched 18 January 2016 in the Cochrane Central Register of Studies Online);</LI>
<LI>MEDLINE (January 1966 to 18 January 2016); and</LI>
<LI>Embase (January 1980 to 18 January 2016).</LI>
</UL>
<P>We also searched the following trials registries in January 2016:</P>
<UL>
<LI>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">clinicaltrials.gov</A>); and</LI>
<LI>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <A HREF="http://www.who.int/ictrp/en/">http://www.who.int/ictrp/en/</A>).</LI>
</UL>
<P>The search strategies are in the appendices: Cochrane Neuromuscular Specialised Register (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), CENTRAL (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), MEDLINE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), Embase (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), ClinicalTrials.gov (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), and WHO ICTRP (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-06-14 10:37:59 +0100" MODIFIED_BY="KLJ ">
<P>We checked the bibliographies in reports of the randomised trials and contacted their authors to identify additional published or unpublished data. We also searched the NHS Economic Evaluation Database and contacted other experts in the field seeking information about additional trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-01-23 16:57:39 +0000" MODIFIED_BY="Ruth Brassington">
<STUDY_SELECTION MODIFIED="2017-01-23 16:57:19 +0000" MODIFIED_BY="Ruth Brassington">
<P>Two review authors (DA and RACH) checked titles and abstracts identified from the searches. Both of these review authors obtained the full texts of all potentially relevant studies and assessed them independently. They decided which trials fitted the inclusion criteria and resolved any disagreements about inclusion criteria by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-01-23 16:57:20 +0000" MODIFIED_BY="Ruth Brassington">
<P>A single review author (DA) performed data extraction and a second review author (SC) checked the data extraction. We obtained missing data from the trial authors whenever possible.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-01-23 16:57:21 +0000" MODIFIED_BY="Ruth Brassington">
<P>Two review authors (DA and RACH) independently assessed the risk of bias in included studies. The assessment of risk of bias followed the methods recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> and took into account random sequence allocation, allocation concealment, participant blinding, observer blinding, incomplete outcome data (completeness of follow-up), selective reporting, and other sources of bias, such as explicit diagnostic criteria, explicit outcome criteria, and how studies dealt with baseline differences between the experimental groups (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We graded the risk as unclear if we were unable to obtain the relevant information. If judgements were inconsistent, we reassessed the studies and reached agreement by consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-01-09 16:11:18 +0000" MODIFIED_BY="Ruth Brassington">
<P>We expressed results as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes and mean differences (MD) with 95% CIs for continuous outcomes. We tried to analyse all the primary and secondary outcomes included in our protocol.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-01-09 16:04:56 +0000" MODIFIED_BY="Ruth Brassington">
<P>For this review, all the trials identified were parallel-group RCTs that did not raise unit of analysis issues.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-09-21 21:18:29 +0100" MODIFIED_BY="Ruth Brassington">
<P>For this review, we did not replace missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-01-18 12:31:07 +0000" MODIFIED_BY="Ruth Brassington">
<P>We tested for heterogeneity using the I² statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We intended to perform a sensitivity analysis with a random-effects model for any unexplained heterogeneity. We found that only one of the many tests of heterogeneity was significant (for <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), so we considered a fixed-effect model appropriate.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-09-21 21:22:16 +0100" MODIFIED_BY="Ruth Brassington">
<P>If we had been able to pool more than 10 trials, we would have created and examined a funnel plot to explore possible small study biases.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-01-23 16:57:31 +0000" MODIFIED_BY="Ruth Brassington">
<P>We calculated a weighted treatment effect (using a fixed-effect model) across trials using the Cochrane statistical package Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">'Summary of findings' table</HEADING>
<P>We created a 'Summary of findings' table with the following outcomes:</P>
<OL>
<LI>walking with aid at four weeks;</LI>
<LI>dependency on a ventilator at four weeks;</LI>
<LI>full muscle strength recovery at one year;</LI>
<LI>relapses at one year;</LI>
<LI>deaths at one year;</LI>
<LI>severe infection.</LI>
</OL>
<P>In the 'Summary of findings' table, we presented an alternative formulation of our primary outcome: 'walking with aid after four weeks' rather than 'time to recover walking with aid'.</P>
<P>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence (studies that contributed data for the prespecified outcomes). For these, we used methods and recommendations described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), using GRADEpro software (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>). We justified all decisions to downgrade or upgrade the quality of studies using footnotes and made comments to aid readers' understanding of the review where necessary.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-01-23 16:57:39 +0000" MODIFIED_BY="Ruth Brassington">
<P>We attempted to analyse subgroups of interest that had been predefined and chosen because of their prognostic importance in prospective studies and trials. The subgroups were defined according to the status of the participants at randomisation as follows:</P>
<OL>
<LI>younger and older (children under 10 years, children over 10 years; and adults up to 49 years of age; adults aged 50 years or more);</LI>
<LI>more severely or less severely affected (walking, not walking or requiring ventilation);</LI>
<LI>having or not having documented relevant sensory deficit on routine neurological examination (symptoms alone were ignored);</LI>
<LI>having or not having a history of diarrhoea (gastroenteritis) within the six weeks before the onset of neuropathic symptoms;</LI>
<LI>time from onset of neuropathy to start of treatment (7 days or less after onset, more than 7 up to 14 days after onset, and more than 14 days after onset);</LI>
<LI>number of plasma exchanges (one, two, and three or more);</LI>
<LI>separation technique: filtration or centrifugation (i.e. continuous or discontinuous);</LI>
<LI>type of replacement fluids, albumin plus gelatin or fresh frozen plasma.</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-01-09 16:05:01 +0000" MODIFIED_BY="Ruth Brassington">
<P>We would have carried out a sensitivity analysis based on study quality (risk of bias) if we had needed to explore heterogeneity. For any unexplained heterogeneity, we would have carried out a sensitivity analysis using a random-effects model.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-03-17 11:03:14 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;The total number of &lt;b&gt;new&lt;/b&gt; papers found by the update searches which were run on 14 April 2015 and 18 January 2016 are&lt;/p&gt;&lt;p&gt;MEDLINE - 56 new papers&lt;/p&gt;&lt;p&gt;EMBASE - 46 new papers&lt;/p&gt;&lt;p&gt;Cochrane Neuromuscular Specialiszed Register - 14 new papers&lt;/p&gt;&lt;p&gt;CENTRAL - 27 new papers&lt;/p&gt;&lt;p&gt;The Neuromuscular Group is now following the Cochrane policy of giving the total number of new references found in each databaseby the update searches, the number of references after deduplication, the number of references selected for further review and the number meeting the inclusion criteria for the review.&lt;/p&gt;&lt;p&gt;The numbers given above are total number of new references retrieved since the last published review.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;The following Databases are included in the Cochrane Library. You may wish to use the results in the discussion section&lt;/p&gt;&lt;p&gt;NHSEED (NHDS Economic Evaluation Database) - 5 papers&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;The new references were deduplicated in the CRS softwate resulting in 112 references&lt;/p&gt;&lt;p&gt;There were also 3 trials in the clinical trials registries.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-03-17 11:03:14 +0000" NOTES_MODIFIED_BY="Ruth Brassington">
<STUDY_DESCRIPTION MODIFIED="2017-01-23 16:57:48 +0000" MODIFIED_BY="Ruth Brassington">
<SEARCH_RESULTS MODIFIED="2017-01-23 16:57:42 +0000" MODIFIED_BY="Ruth Brassington">
<P>The numbers of new papers found by the updated searches in January 2016 were Cochrane Neuromuscular Specialised Register 14, CENTRAL 27, MEDLINE 56, Embase 46, and NHS Economic Evaluation Database 5. There were 112 papers after deduplication. We identified three additional records from the trials registry searches.</P>
<P>The search strategy identified 38 potentially relevant articles. Twenty of these articles were excluded on the basis of the contents of their title and abstract. Two papers were reviews on the general use of plasma exchange, and two others were related to chronic inflammatory demyelinating polyradiculoneuropathy. Eleven papers reported studies that evaluated steroids (one study) or intravenous immunoglobulins (IVIgs) (10 studies); we did not include these as other Cochrane systematic reviews have evaluated these therapies. Two papers were commentaries about treatments for GBS. Three additional papers were related to prognostic factors in GBS. Among the remaining 18 papers, the study by Mendell (<LINK REF="STD-Mendell-1985" TYPE="STUDY">Mendell 1985</LINK>; <LINK REF="REF-Mendell-1985b" TYPE="REFERENCE">Mendell 1985b</LINK>) and the North American study (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="REF-McKhann-1985b" TYPE="REFERENCE">McKhann 1985b</LINK>) were each published in two different papers. Five articles reported complementary information from one single trial (<LINK REF="REF-Bouget-1993" TYPE="REFERENCE">Bouget 1993</LINK>; <LINK REF="REF-Rapha_x00eb_l-1985" TYPE="REFERENCE">Raphaël 1985</LINK>; <LINK REF="REF-Rapha_x00eb_l-1986" TYPE="REFERENCE">Raphaël 1986</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="REF-Rapha_x00eb_l-1992" TYPE="REFERENCE">Raphaël 1992</LINK>) and two other articles reported complementary results from another single trial (<LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>; <LINK REF="REF-Farkkila-1992" TYPE="REFERENCE">Farkkila 1992</LINK>). Another paper reported the results of three different trials (<LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). Hence we identified 14 potentially relevant trials that have evaluated plasma exchange for GBS, eight of which fulfilled predefined selection criteria for inclusion in the review.</P>
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for a flow chart of the study selection process.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-01-23 16:57:48 +0000" MODIFIED_BY="Ruth Brassington">
<P>All the eight included trials had explicit diagnostic criteria similar to those of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Six of the eight trials compared plasma exchange alone to supportive care.</P>
<P>In <LINK REF="STD-Greenwood-1984" TYPE="STUDY">Greenwood 1984</LINK>, 29 participants with GBS within two weeks from onset of motor deficit who were unable to walk without assistance were randomised to receive either five sessions of plasma exchange in five days or only supportive care. At each session, 55 mL/kg of plasma were exchanged and substitution consisted of purified proteins and crystalloid. The primary end point was improvement in disability grade one month after completion of treatment. Participants in both arms were comparable for baseline characteristics, notably for the proportion of participants on ventilator (12/15 versus 8/14), and participants were followed up for one year. Seven of the 14 participants in the treated group improved by one or more grades at one month, compared to 6/15 in the control group. Similarly, after one year, there was no difference between the two arms for the number of deaths (2/14 versus 2/15), for the number of participants who recovered fully (4/14 versus 4/15), or for the number of relapses (1/14 versus 1/15). Two participants in the treated group had episodes of haemorrhage and two additional participants in the treated group had venous thrombosis, while no such complications were seen in the control group.</P>
<P>In <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>, 38 adults with GBS within two weeks from onset of motor deficit who were unable to walk without assistance were randomised to receive either plasma exchange (N = 18) or supportive care (N = 20). In the treatment group, the intermittent flow technique was used in five to eight sessions over seven to 10 days in eight participants. In 10 participants, three or four sessions over three to seven days were done using the continuous flow technique. In each session, a total of 3 L of plasma was removed. The main outcome measure was improvement of muscle strength based on a muscular weakness score and functional disability grade. Analyses were done on an intention-to-treat basis. The two groups were comparable for baseline characteristics, notably for the proportion of participants being on ventilator (2/20 versus 0/18) and follow-up. Six of 20 participants in the control group compared to 14/18 in the treated group improved by one or more disability grades at one month (P &lt; 0.025). After one year, 17/18 (95%) participants in the treated group had complete muscle strength recovery (disability grade 0 or 1) compared to 16/20 (80%) in the control group. No serious adverse events were reported.</P>
<P>In <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>, 245 children and adults with GBS within 30 days from onset of motor deficit who were unable to walk without assistance were randomised to receive either supportive care alone or three to five plasma exchanges in seven to 14 days. At each session, 40 mL/kg of plasma was removed. Substitution consisted of a 5% solution of processed human plasma protein in normal saline in most participants, except for 12 who received fresh frozen plasma. The main outcome measure was proportion of participants who improved at least one grade at one month. Analyses were done on an intention-to-treat basis. Subgroup analyses were defined a priori for participants needing or not needing respiratory assistance and for plasmapheresis technique (centrifugation versus filtration). The two groups were closely similar for baseline characteristics, notably for the proportion of participants being on ventilator (52/123 versus 57/122) and follow-up. Thirty-nine per cent of participants in the control group compared to 59% in the treated group improved by one or more grades at one month (P &lt; 0.01). For participants needing respiratory assistance at inclusion, 35% in the control group compared to 50% in the treated group improved by one or more disability grades at one month (P &lt; 0.01). The median time to recover walking unaided was shortened in the treatment group by 32 days for all participants (P &lt; 0.001), and by 72 days for participants initially on a ventilator (P &lt; 0.01). After six months, 18% in the treated group failed to recover walking unaided compared to 29% in the control group (P &lt; 0.05). The authors found no significant difference in the nature or frequency of serious adverse events in the two arms. The authors provided the comparison between the two techniques for plasma exchange in another paper that is detailed below (<LINK REF="REF-McKhann-1988" TYPE="REFERENCE">McKhann 1988</LINK>).</P>
<P>In <LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>, 29 adults with GBS within two weeks from onset of motor deficit were randomised to receive either three to five sessions of plasma exchange or only supportive care. In each session, a total of 3 L of plasma was removed. The main outcome measure was hand grip force evaluated every day for the first week then every second day the second week after treatment initiation. One participant in the treated group was considered to have a form of relapsing polyradiculoneuritis and two other participants (one in each group) had poliomyelitis and were excluded. The groups of participants were comparable for baseline characteristics, notably for the proportion of participants being on ventilator (3/13 versus 4/13) and follow-up. Isometric muscle force increased faster in the treated group and was significantly greater than in the control group throughout the three-week follow-up period (P &lt; 0.001). The mean (± standard deviation (SD)) time on ventilator was slightly shortened in the treated group (N = 4) compared to the control group (N = 3) (11.7 ± 12.2 days versus 15.3 ± 6.1 days, P = 0.50). The authors did not provide the time to recover walking with aid or the proportion of participants with one or more disability grades improvement at one month. The authors stated that the two groups were comparable after one year, but did not provide any data. The mean time to hospital discharge was slightly reduced in the treated group compared to the control group (48.4 ± 34.5 days versus 53.0 ± 38.9 days, P = 0.26). The mean recovery time was almost identical between the two groups (76.6 ± 88.4 days versus 79.1 ± 55.8 days, P = 0.75). Mild temporary falls in blood pressure were the only reported side effects related to plasma exchange.</P>
<P>In the <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>, 220 adults with GBS within two weeks from onset of motor deficit were randomised to receive either four sessions of plasma exchange in eight days or supportive care. In the treated group, participants were randomised to receive plasma exchange with total volume replacement with fresh frozen plasma or replacement with diluted albumin and gelatine solution, each 50% of the total volume replacement. In each session, a total of 3 L of plasma was removed. The main outcome measure was the time to recover walking with assistance (disability grade 3). Intention-to-treat analyses were performed. Comparison of the Kaplan-Meier curves indicating the proportion of participants who recovered walking with assistance during the 180 days of follow-up showed significantly faster improvement in the plasma exchange group (median, 44 days versus 30 days, one-tailed Breslow test P &lt; 0.01). The number of participants with one or more grade improvement at one month was 67/109 in the treated group compared to 41/111 in the control group (P &lt; 0.001). Separate analyses were done for participants needing mechanical ventilation at randomisation (43/111 versus 39/109). In this subset of participants, the median time to onset of recovering walking with assistance was shorter in the plasma exchange arm compared to the control arm (76 days versus 50 days, P &lt; 0.05). The authors did not find any significant differences between the two types of volume replacement in the plasma exchange group, regardless of the outcome measures. The trial authors found a lower rate of blood pressure instability or bradycardia in the treated group compared to the control group (36% versus 26%, P &lt; 0.05 and 43% versus 25%, P &lt; 0.005, respectively). There were also fewer episodes of lung infection (46% versus 33%, P &lt; 0.05) and a higher proportion of septicaemia (5% versus 13%, P &lt; 0.05) in the plasma exchange arm compared to the control arm. After one year, 14 participants had died, seven in each group (<LINK REF="REF-Rapha_x00eb_l-1992" TYPE="REFERENCE">Raphaël 1992</LINK>). Nine participants were lost to follow-up, six in the control group and three in the treatment group. The authors found that, at one year, a greater proportion of participants had recovered full muscle strength in the treatment group than in the control group (71% versus 52%, P = 0.007).</P>
<P>In <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>, 91 adults with GBS who were able to stand up alone or to walk with assistance (disability grade 1 to 3) were randomised to receive either two sessions of plasma exchange in three days or supportive care. For plasma exchange, fluid replacement consisted of diluted albumin and gelatine solution, each accounting for half of the total volume replaced. In each session, a total of 3 L of plasma was removed. The main outcome measure was the time to onset of motor recovery, defined by improvement of at least two items of a functional muscular score or one item and improvement in cranial nerve function or trunk or respiratory involvement. Intention-to-treat analyses were done. The two arms were comparable for baseline characteristics and follow-up. In the treated group, the median time to onset of motor recovery was significantly shortened compared to the control group (8 days versus 4 days, P = 0.0002). The number of participants with one or more grades of improvement at one month was significantly higher, 26/45 in the treated group compared to 13/46 in the control group (P &lt; 0.001). Two participants discontinued plasma exchange due to adverse events.</P>
<P>Two trials compared two different numbers of sessions of plasma exchange in adults with GBS. As these trials did not have a control group with only supportive care, we did not include them in the meta-analysis of plasma exchange versus supportive care. In <LINK REF="STD-Rapha_x00eb_l-1997b" TYPE="STUDY">Raphaël 1997b</LINK>, 304 adults with GBS who were unable to stand unaided were randomised to receive either four sessions of plasma exchange in nine days (N = 155) or two sessions of plasma exchange in three days (N = 149). For plasma exchange, fluid replacement consisted of diluted albumin and gelatine solution, each accounting for half of the total volume replaced. In each session, a total of 3 L of plasma was removed. The main outcome measure was the time to recover walking with assistance (disability grade 3). Intention-to-treat analyses were done. The two arms had comparable baseline characteristics and follow-up. In the four sessions of plasma exchange group, the median time to recover walking with assistance was significantly shortened compared to the two sessions of plasma exchange group (24 days versus 20 days, P = 0.04). Similarly, the median time on a ventilator and the median time to hospital discharge were significantly shortened in the four sessions of plasma exchange group (37 days versus 25 days, P = 0.005, and 26 days versus 21 days, P = 0.04, respectively). At one year, a higher proportion of participants in the four sessions of plasma exchange group had recovered full muscle strength compared to the two sessions of plasma exchange group (64% versus 48%, P = 0.006). The trial authors found a slightly higher rate of systolic blood pressure instability related to plasma exchange and a higher rate of haematomas at the venous puncture site in the four sessions of plasma exchange arm compared to the two sessions of plasma exchange arm (18% versus 29%, P = 0.04 and 6% versus 15%, P = 0.02, respectively). At one year, there were 11 deaths (7%) in the four sessions of plasma exchange arm (N = 155) and 3 deaths (2%) in the two sessions of plasma exchange arm (N = 149) (P = 0.052).</P>
<P>In the second trial comparing different numbers of plasma exchanges (<LINK REF="STD-Rapha_x00eb_l-1997c" TYPE="STUDY">Raphaël 1997c</LINK>), 161 adults with GBS who needed mechanical ventilation were randomised to receive either six sessions of plasma exchange in 13 days (N = 80) or four sessions of plasma exchange in nine days (N = 81). For plasma exchange, fluid replacement consisted of diluted albumin and gelatine solution, each accounting for half of total volume replacement. In each session, a total of 3 L of plasma was removed. The main outcome measure was the time to recover walking with assistance (disability grade 3). Intention-to-treat analyses were done. The two arms had comparable baseline characteristics and follow-up. The authors did not find any statistically significant difference between the two arms regardless of the outcome measures except for serious adverse events. There was a higher rate of systolic blood pressure instability related to plasma exchange in the six-session plasma exchange group compared to the four-session plasma exchange group (26% versus 46%, P = 0.001). At one year, there were four deaths (5%) in the six-session plasma exchange group (N = 80) and two deaths (2%) in the four-session plasma exchange group (N = 81) (P = 0.44).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-01-23 16:57:48 +0000" MODIFIED_BY="Ruth Brassington">
<P>We excluded six potentially eligible trials (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). One trial had no control group (<LINK REF="STD-de_x002d_Zoysa-1994" TYPE="STUDY">de-Zoysa 1994</LINK>). The second trial compared two different strategies of fluid replacement for plasma exchange in 12 participants with either myasthenia gravis or GBS, and we were unable to obtain separate data for GBS (<LINK REF="STD-Rock-1997" TYPE="STUDY">Rock 1997</LINK>). In the third trial, plasma exchange was compared to plasma perfusion (<LINK REF="STD-Morosetti-1994" TYPE="STUDY">Morosetti 1994</LINK>). Another trial randomised 25 adults with GBS to receive either nine sessions of plasma exchange in 20 days plus prednisone 100 mg orally for 10 days, then 100 mg on alternate days for 20 days and gradually discontinued over the next 21 days, or supportive care alone (<LINK REF="REF-Mendell-1985b" TYPE="REFERENCE">Mendell 1985b</LINK>). The main outcome measure was muscle strength assessed by a 10-point scale, evaluated repeatedly for 24 weeks. Analyses were done on an intention-to-treat basis. The two groups were comparable for baseline characteristics, except for sex ratio (more females in the treated group) and follow-up. The trial authors did not observe any significant difference between the two groups, regardless of the outcome measure. This trial was not included because the intervention involved both plasma exchange and corticosteroids, so the effect of plasma exchange alone could not be determined. One trial compared plasma exchange (five or six sessions for a total of 8 to 12 L of volume replacement) to CSF filtration in 37 adults with GBS (<LINK REF="STD-Wollinsky-2001" TYPE="STUDY">Wollinsky 2001</LINK>). CSF filtration consisted of five or six cycles of 30 mL to 50 mL of CSF filtered and re-instilled daily for 15 consecutive days. The main outcome measure was the improvement in disability grade at four weeks. Analyses were done on an intention-to-treat basis. Twenty participants were assigned to plasma exchange and 17 to CSF filtration. At baseline, there were slightly more participants on mechanical ventilation in the CSF filtration group (5/17) than in the plasma exchange group (2/18), and the median time from onset of disease and randomisation was slightly shorter in the CSF filtration group (3 days, range 1 to 30 days) than in the plasma exchange group (6.5 days, range 1 to 29 days). The median improvement within four weeks was similar in both groups: 0 grades in the CSF filtration group and 0.5 grades in the plasma exchange group. There was no significant difference between the two treatment arms for any of the secondary outcomes. As plasma exchange was compared to CSF filtration, we did not include the trial in the review, but it has been included in another (<LINK REF="REF-Hughes-2011" TYPE="REFERENCE">Hughes 2011</LINK>). The sixth excluded trial (<LINK REF="STD-El-Bayoumi-2011" TYPE="STUDY">El Bayoumi 2011</LINK>) compared plasma exchange to IVIg in children with GBS requiring mechanical ventilation. This trial has been included in the review of IVIg (<LINK REF="REF-Hughes-2014" TYPE="REFERENCE">Hughes 2014</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-01-09 16:05:56 +0000" MODIFIED_BY="Ruth Brassington">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and the 'Risk of bias' tables in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Overall, the eight studies had good methodological quality. Only two studies had inadequate allocation concealment, as they used alternate allocation (<LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>). We graded all trials at high risk of bias for participant blinding. Sham apheresis would have been the only method for participant blinding, and it was thought unethical by all authors. Only two trials made an effort to keep the observer unaware of the treatment to which the participant was assigned (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>). Four trials attempted to minimise potential bias related to unblinded outcome assessment by centralised review of case reports (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-03-17 11:03:14 +0000" MODIFIED_BY="Ruth Brassington">
<P>We created a 'Summary of findings' tables for treatment effects and treatment complications of plasma exchange versus sham exchange or supportive treatment for GBS (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Time after randomisation to recover walking with aid</HEADING>
<P>Only two trials (311 participants) reported this outcome measure (<LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). In the first study (N = 220), the median time to recover walking with aid was significantly shortened in the plasma exchange group compared to the control group (30 days versus 44 days, P &lt; 0.01). In the second study (N = 91), which involved people with mild forms of GBS (see <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK> in <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK> for definition), the median time to recover walking aided was not different (12 days in the plasma exchange group compared to 14 days in the control group (P = 0.80)).</P>
<P>This outcome was also assessed as the proportion of participants who recovered walking with assistance after four weeks.</P>
<P>We pooled the data from three trials (N = 349)(<LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). After four weeks, 73/172 participants in the treated group had recovered walking with aid, significantly more than the 47/177 in the control group (RR 1.60, 95% CI 1.19 to 2.15, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). We considered that there was no important heterogeneity across the trials (I² = 34%; Chi² = 3.04, P = 0.22).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time to onset of motor recovery (for mild GBS, i.e. people able to walk with assistance at inclusion)</HEADING>
<P>One trial provided data on time to onset of motor recovery (<LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>). In this study, the median time of onset of motor recovery was shortened in the plasma exchange group (N = 109) compared to the control group (N = 111), to six days versus 10 days (P &lt; 0.0001).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Change in disability grade (Hughes 1978) four weeks after randomisation</HEADING>
<P>This outcome measure was analysed in two ways at four weeks, first as the number of participants with one or more disability grade change and second as the mean grade change (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>Five trials provided the number of participants with one or more disability grade change at one month (N = 623). Of these participants, 176/308 in the treated group had improved by one or more grades compared to 110/315 in the control group, RR 1.64 (95% CI 1.37 to 1.96) in favour of the plasma exchange group (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>All five trials reported the mean grade change at four weeks. However, <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK> (N = 38) used a different disability scale from all other trials and so we omitted the trial from this analysis. In <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK> (N = 245), the SD of the mean was not available and so we were unable to estimate the MD. The mean grade change was 1.1 grade in the treated group compared to 0.4 grade in the control group (P &lt; 0.001). When pooling the data of the three other trials (N = 340), the MD was -0.97 (95% CI -1.28 to -0.67) grade change in favour of plasma exchange. We also analysed the results by giving empirical values, the largest in the table, to the SDs for <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>. The results were qualitatively similar to those obtained without including <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK> and they were only slightly quantitatively altered. The MD was -0.89 (95% CI -1.14 to -0.63, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) (N = 585).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time to recovery of walking without aid</HEADING>
<P>Two trials (N = 465) reported this outcome measure (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>). The median time to recover walking unaided was significantly shortened in the plasma exchange group compared to the control group in <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK> (N = 245) (53 days versus 85 days, P &lt; 0.001) and in <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK> (N = 220) (70 days versus 111 days, P &lt; 0.001).</P>
<P>We also assessed this outcome as the proportion of participants who recovered walking unaided after four weeks. We were able to pool the data from three trials (349 participants) (<LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). There were 35/172 participants in the treated group compared to 21/177 participants in the control group who had recovered walking without aid after four weeks (RR 1.72, 95% CI 1.06 to 2.79) in favour of plasma exchange (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). There was significant heterogeneity in the results (I² = 75%; Chi² = 7.94, P = 0.02) that could be explained by difference in the severity of illness in one study (<LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>), compared to the two others (<LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>). Indeed <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK> included only participants with mild GBS, who could walk or stand unaided at inclusion. In this study, there was no significant difference between the plasma exchange group and the control group for the proportion of participants who had recovered walking unaided after four weeks. Excluding the data from <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK> removed the heterogeneity and the RR for improvement increased to 3.81 (95% CI 1.61 to 9.06). However, we reported the pooled data of all studies to reflect a 'real' treatment effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dependency on a ventilator</HEADING>
<P>In all trials, the proportion of participants being ventilated at inclusion was not statistically different between the plasma exchange group and the control group. The proportion of participants on the ventilator at four weeks after randomisation was available in five studies for a total of 623 participants. At one month, 44/308 participants in the treated group needed mechanical ventilation compared to 85/315 participants in the control group. The RR of being mechanically ventilated was 0.53 (95% CI 0.39 to 0.74), significantly in favour of the plasma exchange group (see <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time after randomisation to weaning from the ventilator</HEADING>
<P>This outcome was analysed as the mean duration of mechanical ventilation for participants being ventilated at inclusion. This outcome measure could be retrieved from two studies (N = 249). In the first study (N = 29) the mean (SD) duration on the ventilator was 11.7 (12.2) days in the treated group (N = 4) versus 15.3 (6.1) days in the control group (N = 3) (<LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>). In the second study (N = 220), the mean (SD) duration of ventilation was 27.5 (29.3) days in the treated group compared to 33.3 (23.2) days in the control group (<LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>). When we pooled the data of these two studies, the mean time on a ventilator was slightly but not significantly shortened in the treatment group, with a MD of -5.09 days (95% CI -12.94 to 2.76, P = 0.20). In another trial (N = 245), in participants being ventilated before randomisation, the median time on ventilator was slightly reduced in the treatment group (27 days versus 33 days) (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>). This study did not provide the mean and SD values, and we did not include it in the pooled data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Full muscle strength recovery at one year</HEADING>
<P>Information for full muscle strength recovery at one year could be obtained from five trials for a total of 404 participants (<LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>; <LINK REF="STD-Greenwood-1984" TYPE="STUDY">Greenwood 1984</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). Of these participants, 135/199 in the treated group had recovered full muscle strength after one year compared to 112/205 in the control group. Thus, the RR of having recovered full muscle strength after one year was 1.24 (95% CI 1.07 to 1.45, see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> and <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) significantly in favour of treatment with plasma exchange.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Deaths at one year</HEADING>
<P>This outcome measure could be obtained from six trials for a total of 649 participants (<LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>; <LINK REF="STD-Greenwood-1984" TYPE="STUDY">Greenwood 1984</LINK>; <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). There were 15/321 deaths after one year in the treated group, compared to 18/328 in the control group (RR 0.86, 95% CI 0.45 to 1.65; see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> and <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Severe sequelae at one year</HEADING>
<P>This outcome measure could be obtained from six trials (N = 649) (<LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>; <LINK REF="STD-Greenwood-1984" TYPE="STUDY">Greenwood 1984</LINK>; <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). In the treated group, 35/321 participants had severe sequelae after one year, compared to 55/328 in the control group (RR 0.65, 95% CI 0.44 to 0.96; see <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> and <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) in favour of treatment with plasma exchange.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Relapses after six months to one year</HEADING>
<P>Six trials reported data on relapses after six months to one year (N = 649). None of these studies gave the time elapsed between randomisation and relapse. In the treated group, 13/321 participants relapsed within the follow-up period (six months to one year), significantly more than the number who relapsed in the control group, which was 4/328 (RR 2.89, 95% CI 1.05 to 7.93; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> and <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Complications</HEADING>
<P>Three trials N = 556) provided detailed information about serious adverse events during hospital stay (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). Severe infectious events occurred in 93/276 participants in the treated group compared to 104/280 in the control group (RR 0.91, 95% CI 0.73 to 1.13; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). Fifty-two out of 276 participants in the treated group had blood pressure instability compared to 60/280 participants in the control group (RR 0.88, 95% CI 0.64 to 1.22; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Cardiac arrhythmias occurred in 58/276 participants in the treated group compared to 79/280 participants in the control group (RR 0.75, 95% CI 0.56 to 1.00; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). Four out of 276 participants had a pulmonary embolus in the treated group and 4/280 participants in the control group (RR 1.01, 95% CI 0.26 to 4.00; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Discontinuation of plasma exchange</HEADING>
<P>In two studies (N = 67), none of the participants allocated to plasma exchange had to discontinue the treatment <LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>). In <LINK REF="STD-Greenwood-1984" TYPE="STUDY">Greenwood 1984</LINK> (N = 29), 2/14 participants discontinued plasma exchange. In <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK> (N = 245), 12/122 participants had to discontinue plasma exchange, including three participants who refused to pursue the treatment. Nine participants discontinued plasma exchange because complications occurred. In <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK> (N = 220), 16/109 participants discontinued plasma exchange because of complications. In <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK> (N = 91), 2/45 participants discontinued plasma exchange owing to complications.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Younger and older</HEADING>
<P>We found no study that had included children under 10 years old. Only one trial specifically addressed the issue of age, analysed as a continuous variable (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>). In this study, although age was shown to be an independent prognostic factor, plasma exchange had a statistically significant beneficial effect over and above age.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">More severely or less severely affected</HEADING>
<P>Less severely affected people with GBS were defined as those who could walk at inclusion. Only one trial was designed to evaluate the effects of plasma exchange in people with GBS who could walk at randomisation (<LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). In this study, 91 participants were randomised to receive two plasma exchanges (N = 45) or only supportive care (N = 46). This study showed a significant difference between the two groups in favour of treatment with plasma exchange for almost all outcome measures (see <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>). In a second trial (N = 220) only 10 participants could walk unaided at inclusion: three in the control group and seven in the treated group (<LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>). Separate data for this subset of participants were not available.</P>
<P>Trial authors defined more severely affected people with GBS as those on a ventilator at inclusion. Three trials provided separate analyses for the subset of participants on ventilator at randomisation, for a total of 103 ventilator-dependent participants (<LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>; <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>). In <LINK REF="STD-Farkkila-1987" TYPE="STUDY">Farkkila 1987</LINK>, one of four participants in the treated group died compared to none of three in the control group. The mean (± SD) time on ventilator was slightly shorter in the treated group compared to the control group (11.7 ± 12.2 days versus 15.3 ± 6.1 days). Three out of four participants in the treated group recovered full muscular strength after one year compared to all three participants in the control group. The two other trials defined the subgroup analysis of ventilator-dependent participants a priori and the sample size of the population was far more acceptable. In <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>, there were 57 ventilator-dependent participants at randomisation in the treated group and 52 in the control group. Fifty per cent of participants in the treated group had improved by one or more disability grades after one month, compared to 35% in the control group (P = 0.08). There was 0.8 grade improvement in the treated group compared to 0.1 in the control group (P &lt; 0.001). The median time to recover walking unaided was shortened in the treated group compared to the control group (97 days versus 169 days, P &lt; 0.01). Severe sequelae occurred in 26% of the treated group compared to 42% of the control group (P = 0.06). In <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>, 39 participants were ventilator dependent at randomisation in the treated group and 43 participants were ventilator dependent in the control group. The median time to onset of motor recovery was significantly shortened in the treated group compared to the control group (8 days versus 15 days, P &lt; 0.005), as well as the time to recover walking with aid (50 days versus 76 days, P &lt; 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Having or not having documented relevant sensory deficit on routine neurological examination (symptoms alone were ignored)</HEADING>
<P>None of the studies provided data to allow estimation of effects of plasma exchange in the subsets of participants with or without sensory deficit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Having or not having a history of diarrhoea (gastroenteritis) within the six weeks before the onset of neuropathic symptoms</HEADING>
<P>None of the studies provided data to allow estimation of the effects of plasma exchange in the subset of participants with a history of gastroenteritis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Time from onset of neuropathy to start of treatment (7 days or less after onset, more than 7 up to 14 days after onset, and more than 14 days after onset)</HEADING>
<P>Two trials (N = 465) provided separate analyses for the subset of participants based on length of illness before randomisation (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>). Namely, separate analyses were given for the subset of participants with GBS who had a length of illness of seven days or less, and for participants with a length of illness of more than seven days before randomisation. Neither study gave separate results for participants randomised after 14 days after onset. In <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK> (N = 245), the number of participants with a length of illness before randomisation of seven days or less was not given. The median time to improve one or more disability grades was significantly shortened in the treated group compared to the control group both for the subset of participants randomised within seven days (23 days versus 68 days, P &lt; 0.01) and for the subset of participants randomised after seven days up to 30 days (18 days versus 37 days, P = 0.01). The median time to walk without assistance was shortened in the treated group by 40 days for participants randomised before seven days (P &lt; 0.05) and by 35 days for those randomised between days seven and 30 (P &lt; 0.05). In <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK> (N = 220), there were 158 participants randomised within seven days and 62 participants randomised after seven days. The median time to onset of motor recovery was significantly shortened in the treated group compared to the control group, both for the subset of participants randomised within seven days (7 days versus 13 days, P &lt; 0.0001) and for the subset of participants randomised after seven days up to 14 days (6 days versus 13 days, P &lt; 0.005). The median time to recover walking with assistance was also shortened in the plasma exchange group compared to the control group, for the subset of participants randomised within seven days (35 days versus 45 days, P &lt; 0.05). In the subset of participants randomised after seven days (up to 14 days), the median time to recover walking with aid was not significantly different (23 days versus 39 days, P &lt; 0.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Number of plasma exchanges</HEADING>
<P>Only two studies (N = 465) were designed to evaluate the appropriate number of plasma exchanges (<LINK REF="STD-Rapha_x00eb_l-1997b" TYPE="STUDY">Raphaël 1997b</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997c" TYPE="STUDY">Raphaël 1997c</LINK>). In <LINK REF="STD-Rapha_x00eb_l-1997b" TYPE="STUDY">Raphaël 1997b</LINK>, 304 people with GBS who could not stand unaided and who did not need respiratory assistance were randomised to receive either four (N = 155) or two (N = 149) sessions of plasma exchange. This trial showed that, compared to the two-sessions plasma exchange arm, in the four-sessions plasma exchange arm the median time to walk with aid (20 days versus 24 days, P = 0.04) and the median time on the ventilator (15 days versus 37 days, P = 0.005) were shortened. Similarly, the proportion of participants who recovered their full muscle strength after one year was higher in the four-session plasma exchange arm compared to the two-session plasma exchange arm (64% versus 48%, P = 0.006). In the four-session plasma exchange arm, a slightly higher proportion of participants had blood pressure instability (29% versus 18%, P = 0.04) or haematomas at venepuncture sites (15% versus 6%, P = 0.02) than in the two-session plasma exchange arm. In <LINK REF="STD-Rapha_x00eb_l-1997c" TYPE="STUDY">Raphaël 1997c</LINK>, 161 ventilator-dependent GBS participants were randomised to receive either six or four sessions of plasma exchange. There was no significant difference between the two arms in any outcome measure, except for the proportion of participants with systolic blood pressure instability, which was significantly higher in the six-session plasma exchange arm (46% versus 26%, P = 0.001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Separation technique: filtration or centrifugation (i.e. continuous or discontinuous)</HEADING>
<P>We found two studies (N = 465) that addressed the issue of the technique for plasmapheresis, which is plasma exchange with a continuous flow machine versus an intermittent flow machine and cell separation versus filtration technique (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>). The results for these comparisons were published in subsequent papers (<LINK REF="REF-McKhann-1988" TYPE="REFERENCE">McKhann 1988</LINK>; <LINK REF="REF-Rapha_x00eb_l-1992" TYPE="REFERENCE">Raphaël 1992</LINK>). In <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK> (N = 245), in the subset of participants who received plasma exchange with continuous flow machines, a higher proportion of participants improved by one or more grades after one month than participants on intermittent flow machines (64% versus 51%, P &lt; 0.01). The median time to improve by one grade was shortened in the subset of participants treated with continuous flow machines compared to those treated with intermittent flow machines (17 days versus 28 days, P &lt; 0.001). The median time to reach unaided walking was also shortened (48 days versus 62 days, P &lt; 0.01). The authors could not find any other factor that might have explained the observed difference between the two techniques; it could not be explained by the volume of plasma exchanged or treatment on consecutive days. In <LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK> (N = 220), 71% of participants treated with the cell separation technique had full muscle strength recovery after one year compared to 69% in participants who were treated with the filtration technique (P = 0.80). This study did not show a significant difference for full muscle strength recovery after one year between participants treated with continuous machines and those treated with intermittent machines (13/20 versus 8/10, P = 0.68).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Type of replacement fluids: albumin plus gelatin or fresh frozen plasma</HEADING>
<P>We found only one study (N = 220) that addressed the issue of the type of fluid replacement for plasma exchange (<LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>). The results were published in detail in two subsequent papers (<LINK REF="REF-Bouget-1993" TYPE="REFERENCE">Bouget 1993</LINK>; <LINK REF="REF-Rapha_x00eb_l-1992" TYPE="REFERENCE">Raphaël 1992</LINK>). In this study, 57 participants were randomly allocated to receive plasma exchange with albumin and gelatin as replacement fluids and 52 received plasma exchange with fresh frozen plasma as the replacement fluid. The trial authors did not find any significant difference between the two arms in any of the outcomes. During plasma exchange, the decreases in fibrinogen (63% versus 35%) and prothrombin (52% versus 18%) levels were greater in participants who received plasma exchange with albumin as replacement fluid than those who received plasma exchange with fresh frozen plasma (P = 0.0001). The trial authors found a higher rate of adverse events in sessions using fresh frozen plasma as replacement fluid than with albumin (46% versus 32%, P = 0.008).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cost benefits</HEADING>
<P>Though we did not plan to assess this outcome, we found two studies (N = 130) that addressed the issue of cost-effectiveness (<LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK> reported that plasma exchange of the 17 surviving participants in the treated group saved more than 500 days in hospital, at an average cost of more than GBP 100 per day. Thus, it was estimated that plasma exchange saved a total of GBP 50,000 while the total cost of plasma exchange was GBP 2000 per person, which is GBP 38,000 for the 18 participants of the treated group. In the second study, a cost-effectiveness analysis was separately reported (<LINK REF="REF-Esp_x00e9_rou-2000" TYPE="REFERENCE">Espérou 2000</LINK>). In this study, for people with GBS who could stand unaided (disability grade 0 to 3), the total cost was estimated at EUR 20,876 in the two plasma exchange groups compared to EUR 38,877 in the control group. For participants who could not stand, the total cost was estimated at EUR 56,335 in the four-session plasma exchange arm compared to EUR 78,293 in the two-session plasma exchange arm. Finally, in people who were ventilator dependent, the total cost was estimated at EUR 55,983 in the six-session plasma exchange arm compared to EUR 53,221 in the four-session plasma exchange arm.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-01-23 16:58:14 +0000" MODIFIED_BY="Ruth Brassington">
<SUMMARY_OF_RESULTS MODIFIED="2017-01-23 16:58:13 +0000" MODIFIED_BY="Ruth Brassington">
<P>According to moderate quality evidence, plasma exchange improved the majority of outcomes compared to supportive care alone. The time to recover walking with aid, the time to recover walking unaided and the time to improve by one or more disability grades were all shortened by plasma exchange. After four weeks, the combined data from three studies accounting for 349 participants showed that plasma exchange significantly improved the proportion of people with GBS who recovered the ability to walk with assistance. In addition, after four weeks, the combined data from five studies with 623 participants showed that plasma exchange significantly increased the number of participants being improved by one or more disability grade and the mean grade improvement. Plasma exchange shortened the time on ventilator and the proportion of ventilator-dependent participants was significantly decreased. During the hospital stay, plasma exchange did not alter the risk of severe infections or cardiovascular instability, but did significantly reduce the risk of cardiac arrhythmias. Plasma exchange also had longer-term benefits. It increased significantly the number of participants who had recovered full muscle strength and decreased the proportion of participants with severe motor sequelae after one year. However, the RR of relapsing was slightly increased by plasma exchange, which should be taken into account when arranging follow-up.</P>
<P>Plasma exchange had to be discontinued in 0% to 14% of participants in the various trials.</P>
<P>Trials suggested that the appropriate number of plasma exchanges is four sessions for people with moderate to severe GBS (<LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>; <LINK REF="STD-Rapha_x00eb_l-1997b" TYPE="STUDY">Raphaël 1997b</LINK>) and two sessions for those with mild GBS (<LINK REF="STD-Rapha_x00eb_l-1997c" TYPE="STUDY">Raphaël 1997c</LINK>).</P>
<P>The results from one study suggested that plasma exchange might be better performed with continuous flow machines rather than with intermittent machines (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="REF-McKhann-1988" TYPE="REFERENCE">McKhann 1988</LINK>). However, these results were not confirmed in another study (<LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>; <LINK REF="REF-Rapha_x00eb_l-1992" TYPE="REFERENCE">Raphaël 1992</LINK>). In these studies participants were not randomised to receive one or other of these plasma exchange techniques.</P>
<P>The results of one trial (<LINK REF="STD-Rapha_x00eb_l-1987" TYPE="STUDY">Raphaël 1987</LINK>), in which participants were randomised to one or another fluid replacement strategy, suggested that albumin plus gelatin (or alternatively colloids or crystalloids) should be used rather than fresh frozen plasma. Indeed, similar efficacy was shown with each fluid replacement strategy while the risk of disease transmission may be higher with fresh frozen plasma.</P>
<P>Cost analyses derived from two studies showed a reduction of total costs in people with GBS treated by plasma exchange (<LINK REF="REF-Esp_x00e9_rou-2000" TYPE="REFERENCE">Espérou 2000</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-01-23 16:58:14 +0000" MODIFIED_BY="Ruth Brassington">
<P>We found no randomised trial that had assessed the efficacy of plasma exchange in children under 12 years old. For people older than 12 years with GBS, plasma exchange efficacy and tolerance may not be altered by age. According to <LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>, plasma exchange may be more efficacious when performed within seven days of onset of motor deficit rather than later. Nevertheless in the same trial, people with GBS benefited from plasma exchange up to 30 days after disease onset.</P>
<P>The beneficial effect of plasma exchange was observed regardless of the severity of illness. For people with mild GBS, we found only one trial that had evaluated plasma exchange versus supportive care (<LINK REF="STD-Rapha_x00eb_l-1997a" TYPE="STUDY">Raphaël 1997a</LINK>). This was a large RCT with a low risk of bias. The study provided results showing qualitatively and quantitatively similar benefit from plasma exchange to that observed in the various trials that had studied moderate and severe GBS. For people with severe GBS who were ventilator dependent, three trials provided data, which showed that participants from this particular subset also benefit from plasma exchange.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-01-09 16:07:40 +0000" MODIFIED_BY="Ruth Brassington">
<P>For the primary outcome and most of the secondary outcomes we graded the quality of evidence as moderate, downgraded from high because all trials lacked blinding.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-01-20 11:38:49 +0000" MODIFIED_BY="Ruth Brassington">
<P>In this review, we performed a comprehensive search of the literature with no restriction for language, so that there was a very limited risk that we missed important trials. According to the primary objective of this systematic review, only the trials that compared plasma exchange to supportive care alone, or that compared different modalities of plasma exchange, i.e. doses, types of fluids, or separation techniques, were included. Among the six relevant trials included in this review, three were large-scale multicentre trials with low risks of bias. We considered pooling the results of these trials in a meta-analysis acceptable. Participant blinding was never done as all investigators from the various trials agreed that sham plasma exchange is not ethical in people with GBS. Two studies made an effort to obtain assessment of outcomes by blinded observers (<LINK REF="STD-McKhann-1985" TYPE="STUDY">McKhann 1985</LINK>; <LINK REF="STD-Osterman-1984" TYPE="STUDY">Osterman 1984</LINK>).</P>
<P>Except for the studies by the French cooperative group, only published data were available. Consequently, we were unable to evaluate several outcome measures proposed in the protocol for this review. This was particularly the case for the primary end point, time to recover walking with aid (disability grade 3), an outcome of great interest to clinicians. The outcome 'change of one disability grade point at four weeks' was chosen as the primary outcome in many of the trials included in this meta-analysis, and was available in all trials. Thus, it was upgraded to the first secondary outcome for this review. We chose to convert outcome measures that corresponded to censored data into dichotomous variables, that is to say the presence or absence of a particular event or feature after four weeks or after one year.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-01-09 17:28:56 +0000" MODIFIED_BY="Ruth Brassington">
<P>The findings from this review are consistent with the recommendations from evidence-based guidelines for the use of plasmapheresis in neurologic disorders established by the American Academy of Neurology in 2011 (<LINK REF="REF-Cortese-2011" TYPE="REFERENCE">Cortese 2011</LINK>). We are not aware of more recent guidelines.</P>
<P>Following the demonstration of benefit from plasma exchange, IVIg was introduced as an alternative treatment (<LINK REF="REF-Van-der-Mech_x00e9_-1992" TYPE="REFERENCE">Van der Meché 1992</LINK>). Comparison of plasma exchange and IVIg in two randomised trials suggests that both have similar effects (<LINK REF="REF-PSGBS-Group-1997" TYPE="REFERENCE">PSGBS Group 1997</LINK>; <LINK REF="REF-Van-der-Mech_x00e9_-1992" TYPE="REFERENCE">Van der Meché 1992</LINK>). A Cochrane systematic review of IVIg (<LINK REF="REF-Hughes-2014" TYPE="REFERENCE">Hughes 2014</LINK>) and an umbrella review, incorporating the results of this review and those of IVIg and corticosteroids, agreed that IVIg and plasma exchange have equivalent efficacy in GBS (<LINK REF="REF-Hughes-2007" TYPE="REFERENCE">Hughes 2007</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-01-23 16:58:14 +0000" MODIFIED_BY="Ruth Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2017-01-23 16:58:14 +0000" MODIFIED_BY="Ruth Brassington">
<P>Moderate-quality evidence accumulated from six trials uniformly supports the efficacy of plasma exchange in GBS assessed after four weeks or one year. This has been achieved without an increase in serious adverse events. According to one small trial, two sessions of plasma exchange was significantly superior to none in mild GBS. In one trial in moderate and severe GBS, four sessions were significantly superior to two. Non-randomised evidence showed that there is no significant difference in efficacy between continuous and intermittent flow plasma exchange machines. According to one trial albumin with colloids or crystalloids as replacement solutions are not significantly different in efficacy from fresh frozen plasma but are associated with significantly fewer adverse events. Non-randomised evidence showed that plasma exchange started seven days or less after the onset of neuropathy was more efficacious than plasma exchange started later. However, plasma exchange started between seven and 30 days after disease onset was more efficacious than no plasma exchange. There was a small but significant increase in the risk of relapse during the first six to 12 months after onset in people treated with plasma exchange compared with those were not treated.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-09-21 21:34:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>The role of plasma exchange for treating GBS in children under 12 years old and in people with a duration of disease more than 30 days before treatment remain to be evaluated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-01-23 16:58:15 +0000" MODIFIED_BY="Ruth Brassington">
<P>This project was supported by the National Institute for Health Research (NIHR) via Cochrane Infrastructure funding to Cochrane Neuromuscular. The views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service, or the Department of Health. Cochrane Neuromuscular is also supported by the MRC Centre for Neuromuscular Diseases.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-01-23 16:58:18 +0000" MODIFIED_BY="Ruth Brassington">
<P>SC co-ordinated two RCTs that reported a beneficial effect. She has no known commercial conflicts of interest.</P>
<P>RACH holds or held consultancies with the following companies that produce IVIg or immunosuppressive drugs: CSL Behring, LFB, and Novartis. He participated in an RCT that did not report any beneficial effect and co-ordinated another that showed equivalent efficacy of plasma exchange and intravenous immunoglobulin (IVIg).</P>
<P>DA: no known conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-01-23 16:58:16 +0000" MODIFIED_BY="Ruth Brassington">
<P>DA and Jean Claude Raphaël (JCR) prepared the data extraction form for earlier versions of the review. JCR, DA, and SC extracted the data and wrote the first draft. RACH checked the data and edited the first and subsequent drafts. DA entered data onto the computer. All four authors agreed the final text. DA and RACH updated the review in 2001, 2004, 2006, and 2011. JCR died in February 2011. DA, RACH, and SC updated the review in 2016.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-01-09 16:01:32 +0000" MODIFIED_BY="Ruth Brassington">
<P>We added 'Summary of findings' tables and revised the methods used to assess risk of bias in accordance with guidance in the 2011 <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2017-02-10 12:48:40 +0000" MODIFIED_BY="Ruth Brassington">
<P>New evidence on this topic is slow to emerge. The review will be assessed for updating in 2020.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-03-17 11:23:17 +0000" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2015-04-14 13:48:22 +0100" MODIFIED_BY="Angela A Gunn">
<INCLUDED_STUDIES MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="Angela A Gunn">
<STUDY DATA_SOURCE="PUB" ID="STD-Farkkila-1987" MODIFIED="2011-06-14 12:00:28 +0100" MODIFIED_BY="Angela A Gunn" NAME="Farkkila 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-06-14 12:00:28 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Färkkilä M, Kinnunen E, Haapanen E, Livanainen M</AU>
<TI>Guillain Barré syndrome: quantitative measurement of plasma exchange therapy</TI>
<SO>Neurology</SO>
<YR>1987</YR>
<VL>37</VL>
<NO>5</NO>
<PG>837-40</PG>
<IDENTIFIERS MODIFIED="2011-06-14 12:00:28 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806929"/><IDENTIFIER MODIFIED="2011-06-14 12:00:28 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="3553986"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806928"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenwood-1984" MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="Angela A Gunn" NAME="Greenwood 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;Greenwood RJ, Newsom-Davis J, Hughes RAC, Aslan S, Bowden AN, Chadwick DW, Gordon NS, McLellan DL, Millac P, Stott RB, Armitage P. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;1:877-879.&lt;/p&gt;" NOTES_MODIFIED="2012-04-16 15:13:59 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood RJ, Newsom-Davis J, Hughes RAC, Aslan S, Bowden AN, Chadwick DW, et al</AU>
<TI>Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>1</VL>
<NO>8382</NO>
<PG>877-9</PG>
<IDENTIFIERS MODIFIED="2011-06-14 12:01:48 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806931"/><IDENTIFIER MODIFIED="2011-06-14 12:01:48 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="6143188"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806930"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKhann-1985" MODIFIED="2011-06-14 12:02:47 +0100" MODIFIED_BY="Angela A Gunn" NAME="McKhann 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-06-14 12:02:47 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;The Guillain-Barr&amp;#233; syndrome study group. Plasmapheresis and acute Guillain-Barr&amp;#233; syndrome. Neurology 1985;35:1096-1104.&lt;/p&gt;" NOTES_MODIFIED="2011-06-14 12:02:47 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Guillain-Barré syndrome study group</AU>
<TI>Plasmapheresis and acute Guillain-Barré syndrome</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1096-104</PG>
<IDENTIFIERS MODIFIED="2011-06-14 12:02:47 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806933"/><IDENTIFIER MODIFIED="2011-06-14 12:02:47 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="4022342"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806932"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osterman-1984" MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="Angela A Gunn" NAME="Osterman 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Siden A, Safwenberg J. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;2:1296-1299.&lt;/p&gt;" NOTES_MODIFIED="2012-04-16 15:13:59 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Siden A, et al</AU>
<TI>Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>2</VL>
<NO>8415</NO>
<PG>1296-9</PG>
<IDENTIFIERS MODIFIED="2011-06-14 12:03:36 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806935"/><IDENTIFIER MODIFIED="2011-06-14 12:03:36 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="6150321"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806934"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapha_x00eb_l-1987" MODIFIED="2012-04-13 14:03:09 +0100" MODIFIED_BY="Angela A Gunn" NAME="Raphaël 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-06-14 12:04:23 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;French Cooperative Group on plasma exchange in Guillain-Barr&amp;#233; syndrome. Efficiency of plasma exchange in Guillain-Barr&amp;#233; syndrome : role of replacement fluids. Annals of Neurology 1987;22:753-761.&lt;/p&gt;" NOTES_MODIFIED="2011-06-14 12:04:23 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome</AU>
<TI>Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids</TI>
<SO>Annals of Neurology</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>6</NO>
<PG>753-61</PG>
<IDENTIFIERS MODIFIED="2011-06-14 12:04:23 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806937"/><IDENTIFIER MODIFIED="2011-06-14 12:04:23 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="2893583"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-13 14:03:09 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome</AU>
<TI>Plasma exchange in Guillain-Barré syndrome: one year follow-up</TI>
<SO>Annals of Neurology</SO>
<YR>1992</YR>
<VL>32</VL>
<NO>1</NO>
<PG>94-7</PG>
<IDENTIFIERS MODIFIED="2011-06-14 12:11:41 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806938"/><IDENTIFIER MODIFIED="2011-06-14 12:11:41 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="1642477"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806936"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapha_x00eb_l-1997a" MODIFIED="2012-02-20 16:35:23 +0000" MODIFIED_BY="Angela A Gunn" NAME="Raphaël 1997a" YEAR="1997">
<REFERENCE MODIFIED="2011-06-14 12:05:55 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;French Cooperative Group on Plasma Exchange in Guillain-Barr&amp;#233; Syndrome. Appropriate number of plasma exchanges in Guillain-Barr&amp;#233; Syndrome. Annals of Neurology 1997;41:298-306.&lt;/p&gt;" NOTES_MODIFIED="2011-06-14 12:05:55 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome</AU>
<TI>Appropriate number of plasma exchanges in Guillain-Barré Syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>3</NO>
<PG>298-306</PG>
<IDENTIFIERS MODIFIED="2011-06-14 12:05:55 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806940"/><IDENTIFIER MODIFIED="2011-06-14 12:05:55 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="9066350"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806939"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rapha_x00eb_l-1997b" MODIFIED="2012-02-20 16:35:38 +0000" MODIFIED_BY="Angela A Gunn" NAME="Raphaël 1997b" YEAR="1997">
<REFERENCE MODIFIED="2011-06-14 12:06:51 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome</AU>
<TI>Appropriate number of plasma exchanges in Guillain-Barré Syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>3</NO>
<PG>298-306</PG>
<IDENTIFIERS MODIFIED="2011-06-14 12:06:51 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806942"/><IDENTIFIER MODIFIED="2011-06-14 12:06:51 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="9066350"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806941"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rapha_x00eb_l-1997c" MODIFIED="2012-02-20 16:35:48 +0000" MODIFIED_BY="Angela A Gunn" NAME="Raphaël 1997c" YEAR="1997">
<REFERENCE MODIFIED="2011-06-14 12:07:51 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome</AU>
<TI>Appropriate number of plasma exchanges in Guillain-Barré Syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>3</NO>
<PG>298-306</PG>
<IDENTIFIERS MODIFIED="2011-06-14 12:07:51 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806944"/><IDENTIFIER MODIFIED="2011-06-14 12:07:51 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="9066350"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806943"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-04-14 13:48:22 +0100" MODIFIED_BY="Angela A Gunn">
<STUDY DATA_SOURCE="PUB" ID="STD-de_x002d_Zoysa-1994" NAME="de-Zoysa 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de-Zoysa NS, Jayaweera KK, Vaithianathan T</AU>
<TI>Manual plasmapheresis in the treatment of Guillain Barré syndrome</TI>
<SO>Journal of Clinical Apheresis</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>2</NO>
<PG>147-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806946"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806945"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Bayoumi-2011" MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="[Empty name]" NAME="El Bayoumi 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM</AU>
<TI>Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré Syndrome. A randomized study</TI>
<SO>Critical Care</SO>
<YR>2011</YR>
<VL>15</VL>
<PG>R164</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806948"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806947"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendell-1985" MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="Anne Lawson" NAME="Mendell 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, et al</AU>
<TI>Plasma exchange and prednisone in Guillain-Barré syndrome: a controlled randomised trial</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>11</NO>
<PG>1551-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806950"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806949"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morosetti-1994" MODIFIED="2015-04-14 13:48:22 +0100" MODIFIED_BY="Angela A Gunn" NAME="Morosetti 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-04-14 13:48:22 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morosetti M, Meloni C, Taccone Gallucci M, Rossini PM, Felicioni R, Palombo G, et al</AU>
<TI>Plasmapheresis versus plasma perfusion in acute Guillain-Barré syndrome</TI>
<SO>ASAIO Journal</SO>
<YR>1994</YR>
<VL>40</VL>
<NO>3</NO>
<PG>M638-42</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:48:22 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806952"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806951"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rock-1997" MODIFIED="2012-04-16 14:17:43 +0100" MODIFIED_BY="Anne Lawson" NAME="Rock 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-04-16 14:17:43 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rock G</AU>
<TI>Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange. The Canadian Apheresis Group</TI>
<SO>Journal of Clinical Apheresis</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>4</NO>
<PG>165-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806954"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806953"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wollinsky-2001" MODIFIED="2012-04-16 14:17:35 +0100" MODIFIED_BY="Anne Lawson" NAME="Wollinsky 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-04-16 14:17:35 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wollinsky KH, Hulser PJ, Brinkmeier H, Aulkemeyer P, Bossenecker W, Huber-Hartmann KH, et al</AU>
<TI>CSF filtration is an effective treatment of Guillain Barré syndrome: a randomized clinical trial</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>5</NO>
<PG>774-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2806956"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2806955"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Asbury-1990" MODIFIED="2017-01-20 11:38:01 +0000" MODIFIED_BY="Ruth Brassington" NAME="Asbury 1990" TYPE="JOURNAL_ARTICLE">
<AU>Asbury AK, Cornblath DR</AU>
<TI>Assessment of current diagnostic criteria for Guillain-Barré syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1990</YR>
<VL>27 Suppl</VL>
<PG>S21-4</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:48:45 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Bouget-1993" MODIFIED="2017-01-20 11:37:50 +0000" MODIFIED_BY="Ruth Brassington" NAME="Bouget 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bouget J, Chevret S, Chastang C, Raphael JC</AU>
<TI>Plasma exchange morbidity in Guillain Barré syndrome: results from the French prospective, randomized, multicenter study. The French Cooperative Group</TI>
<SO>Critical Care Medicine</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>5</NO>
<PG>651-8</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:49:03 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Brettle-1978" MODIFIED="2015-04-14 13:51:15 +0100" MODIFIED_BY="Angela A Gunn" NAME="Brettle 1978" TYPE="JOURNAL_ARTICLE">
<AU>Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C</AU>
<TI>Treatment of acute polyneuropathy by plasma exchange</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>2</VL>
<NO>8099</NO>
<PG>1100</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:51:15 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Consensus-1986" MODIFIED="2015-04-14 13:51:27 +0100" MODIFIED_BY="Angela A Gunn" NAME="Consensus 1986" TYPE="JOURNAL_ARTICLE">
<AU>Consensus Conference</AU>
<TI>The utility of therapeutic plasmapheresis for neurological disorders</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1986</YR>
<VL>256</VL>
<NO>10</NO>
<PG>1333-7</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:51:27 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Cook-1971" MODIFIED="2015-04-14 13:51:40 +0100" MODIFIED_BY="Angela A Gunn" NAME="Cook 1971" TYPE="JOURNAL_ARTICLE">
<AU>Cook SD, Dowling PC, Murray MR, Whitaker JN</AU>
<TI>Circulating demyelinating factors in acute idiopathic polyneuropathy</TI>
<SO>Archives of Neurology</SO>
<YR>1971</YR>
<VL>24</VL>
<NO>2</NO>
<PG>136-44</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:51:40 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Cortese-2011" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NAME="Cortese 2011" TYPE="JOURNAL_ARTICLE">
<AU>Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A</AU>
<TI>Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>2011</YR>
<VL>76</VL>
<NO>3</NO>
<PG>294-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Esp_x00e9_rou-2000" NAME="Espérou 2000" TYPE="JOURNAL_ARTICLE">
<AU>Espérou H, Jars Guincestre MC, Bolgert F, Raphael JC, Durand-Zaleski I, and the French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome</AU>
<TI>Cost-effectiveness of plasma exchange therapy for the treatment of Guillain-Barré syndrome</TI>
<SO>Intensive Care Medicine</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>8</NO>
<PG>1094-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farkkila-1992" MODIFIED="2015-04-14 13:51:57 +0100" MODIFIED_BY="Angela A Gunn" NAME="Farkkila 1992" TYPE="JOURNAL_ARTICLE">
<AU>Farkkila M, Penttila P</AU>
<TI>Plasma exchange therapy reduces the nursing care needed in Guillain-Barré syndrome</TI>
<SO>Journal of Advanced Nursing</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>6</NO>
<PG>672-5</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:51:57 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2017-01-09 16:08:21 +0000" MODIFIED_BY="Ruth Brassington" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>Jan Brozek, Andrew Oxman, Holger Schünemann</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harrison-1984" MODIFIED="2015-04-14 13:52:05 +0100" MODIFIED_BY="Angela A Gunn" NAME="Harrison 1984" TYPE="JOURNAL_ARTICLE">
<AU>Harrison BM, Hansen LA, Pollard JD, Mc Leod JG</AU>
<TI>Demyelination induced by serum from patients with Guillain-Barré syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1984</YR>
<VL>15</VL>
<NO>2</NO>
<PG>163-70</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:52:05 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="Ruth Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-1978" MODIFIED="2015-04-14 13:52:21 +0100" MODIFIED_BY="Angela A Gunn" NAME="Hughes 1978" TYPE="JOURNAL_ARTICLE">
<AU>Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM</AU>
<TI>Controlled trial of prednisolone in acute polyneuropathy</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>2</VL>
<NO>8104-5</NO>
<PG>750-3</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:52:21 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2007" MODIFIED="2017-01-23 16:59:35 +0000" MODIFIED_BY="Ruth Brassington" NAME="Hughes 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hughes RA, Swan AV, Raphael JC, Annane D, Van Koningsveld, Van Doorn PA</AU>
<TI>Immunotherapy for Guillain-Barré syndrome: a systematic review</TI>
<SO>Brain</SO>
<YR>2007</YR>
<VL>130</VL>
<NO>Pt 9</NO>
<PG>2245-57</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:52:31 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2011" MODIFIED="2015-04-14 13:52:45 +0100" MODIFIED_BY="Angela A Gunn" NAME="Hughes 2011" TYPE="COCHRANE_REVIEW">
<AU>Hughes RA, Pritchard J, Hadden RD</AU>
<TI>Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>3</NO>
<PG>CD008630</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:52:45 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER MODIFIED="2012-04-16 15:15:52 +0100" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD008630.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2014" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NAME="Hughes 2014" TYPE="COCHRANE_REVIEW">
<AU>Hughes RA, Swan AV, Van Doorn PA</AU>
<TI>Intravenous immunoglobulin for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>9</NO>
<PG>CD002063</PG>
<IDENTIFIERS MODIFIED="2017-01-09 17:36:21 +0000" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2017-01-09 17:36:21 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD002063.pub6"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mark-1980" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NAME="Mark 1980" TYPE="JOURNAL_ARTICLE">
<AU>Mark B, Hurwitz J, Olanow CW, Fay JW</AU>
<TI>Plasmapheresis in idiopathic inflammatory polyradiculoneuropathy</TI>
<SO>Neurology</SO>
<YR>1980</YR>
<VL>30</VL>
<NO>4</NO>
<PG>361</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKhann-1985b" MODIFIED="2012-04-13 14:04:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="McKhann 1985b" TYPE="JOURNAL_ARTICLE">
<AU>The Guillain-Barré Syndrome Study Group</AU>
<TI>The North American study of plasmapheresis in the Guillain-Barré syndrome</TI>
<SO>Journal of Clinical Apheresis</SO>
<YR>1985</YR>
<VL>2</VL>
<PG>315-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKhann-1988" MODIFIED="2015-04-14 13:53:04 +0100" MODIFIED_BY="Angela A Gunn" NAME="McKhann 1988" TYPE="JOURNAL_ARTICLE">
<AU>McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA, et al</AU>
<TI>Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis</TI>
<SO>Annals of Neurology</SO>
<YR>1988</YR>
<VL>23</VL>
<NO>4</NO>
<PG>347-53</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:53:04 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Mendell-1985b" MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="Ruth Brassington" NAME="Mendell 1985b" TYPE="JOURNAL_ARTICLE">
<AU>Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, et al</AU>
<TI>Plasma exchange and prednisone in acute inflammatory polyradiculoneuropathy: a controlled randomized trial</TI>
<SO>Journal of Clinical Apheresis</SO>
<YR>1985</YR>
<VL>2</VL>
<NO>4</NO>
<PG>332-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Metral-1989" MODIFIED="2015-04-14 13:53:15 +0100" MODIFIED_BY="Angela A Gunn" NAME="Metral 1989" TYPE="JOURNAL_ARTICLE">
<AU>Metral S, Raphaël JC, Hort-Legrand CL, Elkharrat D</AU>
<TI>Serum demyelinating activity and Guillain-Barre syndrome: favorable effect of plasma exchange</TI>
<TO>Activité démyélinisante sérique et syndrome de Guillain-Barré: effet favorable des échanges plasmatiques</TO>
<SO>Revue Neurologique</SO>
<YR>1989</YR>
<VL>145</VL>
<NO>4</NO>
<PG>312-9</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:53:15 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-PSGBS-Group-1997" MODIFIED="2015-04-14 13:53:26 +0100" MODIFIED_BY="Angela A Gunn" NAME="PSGBS Group 1997" TYPE="JOURNAL_ARTICLE">
<AU>Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group</AU>
<TI>Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9047</NO>
<PG>225-30</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:53:26 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-1985" NAME="Raphaël 1985" TYPE="JOURNAL_ARTICLE">
<AU>Raphael JC, Chastang C, and the Cooperative French Group</AU>
<TI>Cooperative randomized trial of plasma exchange in Guillain-Barré syndrome</TI>
<SO>Plasma Therapy and Transfusion Technology</SO>
<YR>1985</YR>
<VL>6</VL>
<PG>603-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-1986" NAME="Raphaël 1986" TYPE="JOURNAL_ARTICLE">
<AU>Raphael JC, Chastang C</AU>
<TI>Cooperative randomized trial of plasma exchange in the Guillain-Barré syndrome. Short term effects and comparison of diluted albumin and fresh frozen plasma</TI>
<SO>Life Support System</SO>
<YR>1986</YR>
<VL>4</VL>
<PG>329-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-1992" MODIFIED="2017-01-18 16:30:21 +0000" MODIFIED_BY="Ruth Brassington" NAME="Raphaël 1992" TYPE="JOURNAL_ARTICLE">
<AU>French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome</AU>
<TI>Plasma exchange in Guillain-Barré syndrome: one-year follow-up</TI>
<SO>Annals of Neurology</SO>
<YR>1992</YR>
<VL>32</VL>
<NO>1</NO>
<PG>94-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-1996" MODIFIED="2015-04-14 13:53:42 +0100" MODIFIED_BY="Angela A Gunn" NAME="Raphaël 1996" TYPE="JOURNAL_ARTICLE">
<AU>Raphaël JC, Chevret S, Jars-Guincestre MC, Chastang C, Gajdos PH</AU>
<TI>Treatment of Guillain-Barré syndrome by plasma exchange: proposal of a therapeutic strategy</TI>
<TO>Traitement du syndrome de Guillain-Barré par les échanges plasmatiques: proposition d&#8217;une stratégie thérapeutique</TO>
<SO>Revue Neurologique</SO>
<YR>1996</YR>
<VL>152</VL>
<NO>5</NO>
<PG>359-64</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:53:42 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2017-01-20 11:38:34 +0000" MODIFIED_BY="Ruth Brassington" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ropper-1980" NAME="Ropper 1980" TYPE="JOURNAL_ARTICLE">
<AU>Ropper AH, Shahani B, Huggins CE</AU>
<TI>Improvement in four patients with acute Guillain-Barré syndrome after plasma exchange</TI>
<SO>Neurology</SO>
<YR>1980</YR>
<VL>30</VL>
<PG>361</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schooneman-1981" MODIFIED="2012-04-16 15:13:59 +0100" MODIFIED_BY="Anne Lawson" NAME="Schooneman 1981" TYPE="JOURNAL_ARTICLE">
<AU>Schooneman F, Janot C, Streiff F, Gérard A, Dureux JB, Canton P, et al</AU>
<TI>Plasma exchange in Guillain-Barré syndrome ten cases</TI>
<SO>Plasmapheresis Therapy</SO>
<YR>1981</YR>
<VL>2</VL>
<PG>117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shumak-1984" MODIFIED="2015-04-14 13:53:55 +0100" MODIFIED_BY="Angela A Gunn" NAME="Shumak 1984" TYPE="JOURNAL_ARTICLE">
<AU>Shumak KH, Rock GA</AU>
<TI>Therapeutic plasma exchange</TI>
<SO>New England Journal of Medicine</SO>
<YR>1984</YR>
<VL>310</VL>
<NO>1212</NO>
<PG>762-71</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:53:55 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Sumner-1982" NAME="Sumner 1982" TYPE="JOURNAL_ARTICLE">
<AU>Sumner A, Said G, Idy I, Metral S</AU>
<TI>Electrophysiological and morphological effects of the injection of Guillain-Barré sera in the sciatic nerve of the rat</TI>
<TO>Syndrome de Guillain-Barré. Effects electro-physiologiques du sérum humain introduit dans l'espace endoneural du nerf sciatique du rat. Résultats préliminaires</TO>
<SO>Revue Neurologique</SO>
<YR>1982</YR>
<VL>138</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1982249353"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Valbonesi-1981" MODIFIED="2015-04-14 13:54:08 +0100" MODIFIED_BY="Angela A Gunn" NAME="Valbonesi 1981" TYPE="JOURNAL_ARTICLE">
<AU>Valbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I</AU>
<TI>Plasma exchange as a therapy for Guillain-Barré syndrome with immune complexes</TI>
<SO>Vox Sanguinis</SO>
<YR>1981</YR>
<VL>41</VL>
<PG>74-8</PG>
<IDENTIFIERS MODIFIED="2015-04-14 13:54:08 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Mech_x00e9_-1992" MODIFIED="2017-01-09 17:28:56 +0000" MODIFIED_BY="Ruth Brassington" NAME="Van der Meché 1992" TYPE="JOURNAL_ARTICLE">
<AU>Van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group</AU>
<TI>A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<NO>17</NO>
<PG>1123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Visser-1999" MODIFIED="2017-01-23 17:00:13 +0000" MODIFIED_BY="Ruth Brassington" NAME="Visser 1999" TYPE="JOURNAL_ARTICLE">
<AU>Visser LH, Schmitz PI, Meulstee J, Van Doorn PA, Van der Meché FG</AU>
<TI>Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>3</NO>
<PG>598-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Willison-2016" MODIFIED="2017-01-23 17:00:24 +0000" MODIFIED_BY="Ruth Brassington" NAME="Willison 2016" TYPE="JOURNAL_ARTICLE">
<AU>Willison HJ, Jacobs BC, Van Doorn PA</AU>
<TI>Guillain-Barré syndrome</TI>
<SO>Lancet</SO>
<YR>2016</YR>
<VL>388</VL>
<PG>717-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yuki-2012" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NAME="Yuki 2012" TYPE="JOURNAL_ARTICLE">
<AU>Yuki N, Hartung HP</AU>
<TI>Guillain-Barré syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>366</VL>
<NO>24</NO>
<PG>2294-304</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-01-09 17:34:28 +0000" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Raphael-2012" MODIFIED="2017-01-09 17:34:06 +0000" MODIFIED_BY="Ruth Brassington" NAME="Raphael 2012" TYPE="COCHRANE_REVIEW">
<AU>Raphaël JC, Chevret S, Hughes RAC, Annane D</AU>
<TI>Plasma exchange for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2017-01-09 17:34:06 +0000" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2017-01-09 17:34:06 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001798.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-2001" MODIFIED="2017-01-09 17:34:28 +0000" MODIFIED_BY="Ruth Brassington" NAME="Raphaël 2001" TYPE="COCHRANE_REVIEW">
<AU>Raphaël JC, Chevret S, Hughes RA, Annane D</AU>
<TI>Plasma exchange for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-01-09 17:34:28 +0000" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2017-01-09 17:34:28 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001798"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-2002" MODIFIED="2012-01-11 05:11:39 +0000" MODIFIED_BY="Ruth Brassington" NAME="Raphaël 2002" TYPE="COCHRANE_REVIEW">
<AU>Raphaël JC, Chevret S, Hughes RAC, Annane D</AU>
<TI>Plasma exchange for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-09-16 11:53:27 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2011-09-16 11:53:27 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001798"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-01-23 16:58:21 +0000" MODIFIED_BY="Ruth Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-01-23 16:58:21 +0000" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-01-23 16:58:18 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Farkkila-1987">
<CHAR_METHODS MODIFIED="2011-09-09 17:58:58 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, single centre, open, parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-23 16:58:18 +0000" MODIFIED_BY="Ruth Brassington">
<P>N = 29, acute GBS only<BR/>Adults only<BR/>No mild forms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-16 14:23:45 +0100" MODIFIED_BY="[Empty name]">
<P>Plasma exchange versus supportive care<BR/>3 to 5 plasma exchange, 3 L per plasma exchange, diluted albumin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 15:18:44 +0000" MODIFIED_BY="[Empty name]">
<P>Hand-grip force at 3 weeks after first plasma exchange</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-16 14:23:45 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-23 16:58:19 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Greenwood-1984">
<CHAR_METHODS MODIFIED="2012-04-16 14:23:52 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multicentre, open, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-23 16:58:19 +0000" MODIFIED_BY="Ruth Brassington">
<P>N = 29, acute GBS only<BR/>All ages<BR/>No mild forms<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-16 14:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>Plasma exchange versus supportive care<BR/>5 plasma exchange in 5 days, 55 mL/kg per plasma exchange</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 14:47:43 +0000" MODIFIED_BY="Ruth Brassington">
<P>Functional ability at 4 weeks after completion of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-16 14:23:54 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-23 16:58:19 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-McKhann-1985">
<CHAR_METHODS MODIFIED="2012-02-06 19:30:16 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, multicentre, open, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-23 16:58:19 +0000" MODIFIED_BY="Ruth Brassington">
<P>N = 245, acute GBS only<BR/>All ages<BR/>No mild forms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-16 14:23:55 +0100" MODIFIED_BY="[Empty name]">
<P>Plasma exchange versus supportive care<BR/>3 to 5 plasma exchange in 5 days, 40 mL/kg per plasma exchange</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Functional ability at 4 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-16 14:23:55 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-23 16:58:20 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Osterman-1984">
<CHAR_METHODS>
<P>RCT, multicentre, open, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-23 16:58:20 +0000" MODIFIED_BY="Ruth Brassington">
<P>N = 38, acute GBS only<BR/>Adults only<BR/>No mild forms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-16 14:23:57 +0100" MODIFIED_BY="[Empty name]">
<P>Plasma exchange versus supportive care<BR/>3 to 8 plasma exchanges in 7 to 10 days, 3 L per plasma exchange</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle weakness score from randomisation to 6 months<BR/>Functional ability at 4 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-16 14:23:57 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-23 16:58:20 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rapha_x00eb_l-1987">
<CHAR_METHODS>
<P>RCT, multicentre, open, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-23 16:58:20 +0000" MODIFIED_BY="Ruth Brassington">
<P>N = 220, acute GBS only<BR/>Adults only<BR/>All forms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-16 14:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>Plasma exchange versus supportive care<BR/>4 plasma exchange in 8 days, 3 litres per plasma exchange, diluted albumin or fresh frozen plasma</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to recover walking with assistance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-23 16:58:20 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rapha_x00eb_l-1997a">
<CHAR_METHODS MODIFIED="2012-04-16 14:23:59 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multicentre, open, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-23 16:58:20 +0000" MODIFIED_BY="Ruth Brassington">
<P>N = 91, acute GBS only<BR/>Adults only<BR/>Mild forms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-16 14:24:00 +0100" MODIFIED_BY="[Empty name]">
<P>Plasma exchange versus supportive care<BR/>2 plasma exchange every other days, 3 L per plasma exchange, diluted albumin + gelatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to onset of motor recovery</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-16 14:24:00 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-23 16:58:21 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rapha_x00eb_l-1997b">
<CHAR_METHODS MODIFIED="2012-04-16 14:24:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multicentre, open, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-23 16:58:21 +0000" MODIFIED_BY="Ruth Brassington">
<P>N = 304, acute GBS only<BR/>Adults only<BR/>Moderate forms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-16 14:24:01 +0100" MODIFIED_BY="[Empty name]">
<P>2 plasma exchange versus 4 plasma exchange,<BR/>3 L per plasma exchange, diluted albumin + gelatin, plasma exchange every other day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to recover walking with assistance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-16 14:24:02 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-01-23 16:58:21 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rapha_x00eb_l-1997c">
<CHAR_METHODS MODIFIED="2012-04-16 14:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multicentre, open, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-23 16:58:21 +0000" MODIFIED_BY="Ruth Brassington">
<P>N = 161, acute GBS only<BR/>Adults only<BR/>Severe (mechanically ventilated) forms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-05 15:18:17 +0000" MODIFIED_BY="Ruth Brassington">
<P>4 plasma exchange versus 6 plasma exchange<BR/>3 litres per plasma exchange, diluted albumin + gelatin, plasma exchange every other day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to recover walking with assistance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-16 14:24:03 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>GBS: Guillain-Barré syndrome; RCT: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-01-09 16:07:45 +0000" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-09-09 18:13:50 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-de_x002d_Zoysa-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-09 18:13:50 +0100" MODIFIED_BY="Ruth Brassington">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-26 16:29:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El-Bayoumi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-26 16:29:02 +0100" MODIFIED_BY="[Empty name]">
<P>Plasma exchange was compared to intravenous immunoglobulin in children being ventilated for severe GBS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-09 18:07:31 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Mendell-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-09 18:07:31 +0100" MODIFIED_BY="Ruth Brassington">
<P>The study evaluated the effects of the combination of plasma exchange and corticosteroids versus supportive care and not of plasma exchange alone versus supportive care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-09 18:07:34 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Morosetti-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-09 18:07:34 +0100" MODIFIED_BY="Ruth Brassington">
<P>Plasma exchange was compared to plasma perfusion and not to conservative treatment alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-09 16:07:45 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rock-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-09 16:07:45 +0000" MODIFIED_BY="Ruth Brassington">
<P>The study population was made up of participants with GBS and participants with myasthenia gravis. Separate data for participants with GBS could not be obtained</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-09 18:08:14 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Wollinsky-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-09 18:08:14 +0100" MODIFIED_BY="Ruth Brassington">
<P>Plasma exchange was compared to cerebrospinal fluid filtration and not to conservative treatment alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>GBS: Guillain-Barré syndrome.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-01-09 16:07:44 +0000" MODIFIED_BY="Ruth Brassington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-01-11 05:02:23 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farkkila-1987">
<DESCRIPTION>
<P>There is no description of the method used for generating the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenwood-1984">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McKhann-1985">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Osterman-1984">
<DESCRIPTION>
<P>Alternate randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1987">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997a">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997b">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997c">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farkkila-1987">
<DESCRIPTION>
<P>They used alternate allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenwood-1984">
<DESCRIPTION>
<P>Centralisation of the randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McKhann-1985">
<DESCRIPTION>
<P>Centralisation of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Osterman-1984">
<DESCRIPTION>
<P>Alternate randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1987">
<DESCRIPTION>
<P>Centralisation of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997a">
<DESCRIPTION>
<P>Centralisation of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997b">
<DESCRIPTION>
<P>Centralisation of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997c">
<DESCRIPTION>
<P>Centralisation of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-04-16 14:24:03 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-11 05:02:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farkkila-1987">
<DESCRIPTION>
<P>The trial was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Greenwood-1984">
<DESCRIPTION>
<P>Trial was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-16 14:23:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McKhann-1985">
<DESCRIPTION>
<P>Unblinded trial; nevertheless observer remained blinded, and centralised review of case reports</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-16 14:23:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Osterman-1984">
<DESCRIPTION>
<P>Non-blinded trial, nevertheless observers remained blinded, and centralised review of case reports</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-16 14:23:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rapha_x00eb_l-1987">
<DESCRIPTION>
<P>Non-blinded trial, nevertheless the authors used a centralised review of case reports</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-16 14:24:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rapha_x00eb_l-1997a">
<DESCRIPTION>
<P>Non-blinded trial, nevertheless the authors used a centralised review of case reports</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-16 14:24:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rapha_x00eb_l-1997b">
<DESCRIPTION>
<P>Non-blinded trial, nevertheless the authors used a centralised review of case reports</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-16 14:24:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rapha_x00eb_l-1997c">
<DESCRIPTION>
<P>Non-blinded trial, nevertheless the authors used a centralised review of case reports</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-01-09 16:07:43 +0000" MODIFIED_BY="Ruth Brassington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.04 CMP-002.01 CMP-002.03 CMP-002.04">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-09 16:07:43 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Farkkila-1987">
<DESCRIPTION>
<P>3/29 participants (1 in the experimental arm and 2 in the control arm) were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenwood-1984">
<DESCRIPTION>
<P>No loss to follow-up, intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McKhann-1985">
<DESCRIPTION>
<P>No loss to follow-up, intention- to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osterman-1984">
<DESCRIPTION>
<P>No loss to follow-up, intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1987">
<DESCRIPTION>
<P>4% lost to follow-up, intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997a">
<DESCRIPTION>
<P>No loss to follow-up, intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-11 05:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997b">
<DESCRIPTION>
<P>No loss to follow-up, intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-11 05:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997c">
<DESCRIPTION>
<P>No loss to follow-up, intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-01-09 16:07:44 +0000" MODIFIED_BY="Ruth Brassington" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:07:44 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Farkkila-1987">
<DESCRIPTION>
<P>The authors did not provide the time to recover walking with aid or the proportion of participants with 1 or more disability grades' improvement at 1 month. The authors stated that the 2 groups were comparable after 1 year, but did not provide any data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenwood-1984">
<DESCRIPTION>
<P>Data reported for all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McKhann-1985">
<DESCRIPTION>
<P>Data reported for all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osterman-1984">
<DESCRIPTION>
<P>Data reported for all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1987">
<DESCRIPTION>
<P>Data reported for all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997a">
<DESCRIPTION>
<P>Data reported for all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997b">
<DESCRIPTION>
<P>Data reported for all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 05:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997c">
<DESCRIPTION>
<P>Data reported for all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-11-11 12:53:26 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-11-11 12:53:26 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-01-09 16:07:44 +0000" MODIFIED_BY="Ruth Brassington" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-09 16:07:44 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Farkkila-1987">
<DESCRIPTION>
<P>Problems with diagnostic criteria and 3 participants did not have GBS, 1 had a form of relapsing polyradiculoneuritis and 2 other participants (1 in each group) had poliomyelitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenwood-1984">
<DESCRIPTION>
<P>Explicit diagnostic criteria, explicit outcome criteria, no imbalance in baseline characteristics between treatment arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McKhann-1985">
<DESCRIPTION>
<P>Explicit diagnostic criteria, explicit outcome criteria, no imbalance in baseline characteristics between treatment arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osterman-1984">
<DESCRIPTION>
<P>Explicit diagnostic criteria, explicit outcome criteria, no imbalance in baseline characteristics between treatment arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1987">
<DESCRIPTION>
<P>Explicit diagnostic criteria, explicit outcome criteria, no imbalance in baseline characteristics between treatment arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997a">
<DESCRIPTION>
<P>Explicit diagnostic criteria, explicit outcome criteria, no imbalance in baseline characteristics between treatment arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997b">
<DESCRIPTION>
<P>Explicit diagnostic criteria, explicit outcome criteria, no imbalance in baseline characteristics between treatment arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-30 13:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1997c">
<DESCRIPTION>
<P>Explicit diagnostic criteria, explicit outcome criteria, no imbalance in baseline characteristics between treatment arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-03-17 11:21:01 +0000" MODIFIED_BY="Ruth Brassington">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-03-17 11:21:01 +0000" MODIFIED_BY="Ruth Brassington" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-01-18 15:46:26 +0000" MODIFIED_BY="Ruth Brassington">Plasma exchange compared to sham exchange or supportive treatment for Guillain-Barré syndrome</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TD COLSPAN="7">
<P>
<B>Plasma exchange compared to sham exchange or supportive treatment for Guillain-Barré syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with Guillain-Barré syndrome<BR/>
<B>Settings:</B> hospital<BR/>
<B>Intervention:</B> plasma exchange<BR/>
<B>Comparison: </B>sham exchange or supportive treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Sham exchange or supportive treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Plasma exchange</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Walking with aid at 4 weeks</B>
<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.60</B>
<BR/>(1.19 to 2.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>349<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>266 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>425 per 1000</B>
<BR/>(316 to 571)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Dependency on a ventilator at 4 weeks</B>
<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.53 </B>
<BR/>(0.39 to 0.74)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>623<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Plasma exchange therapy reduced the risk of being ventilator dependent at 4 weeks</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>270 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>143 per 1000</B>
<BR/>(105 to 200)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Full muscle strength recovery at 1 year</B>
<BR/>Follow-up: mean 1 year</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.24 </B>
<BR/>(1.07 to 1.45)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>404<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Plasma exchange therapy increased the chance of full recovery at 1 year</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>546 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>677 per 1000</B>
<BR/>(585 to 792)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relapses at 1 year</B>
<BR/>Follow-up: 6 to 12 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 2.89 </B>
<BR/>(1.05 to 7.93)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>649<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Plasma exchange therapy was associated with a higher risk of relapsing at 1 year</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>35 per 1000</B>
<BR/>(13 to 97)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Deaths at 1 year</B>
<BR/>Follow-up: mean 1 year</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.45 to 1.65)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>649<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>55 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>47 per 1000</B>
<BR/>(25 to 91)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Severe infection</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.91 </B>
<BR/>(0.73 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>556<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>371 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>338 per 1000</B>
<BR/>(271 to 420)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Trials were not blinded.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-07-26 16:40:15 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington">
<COMPARISON ID="CMP-001" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="1">
<NAME>Plasma exchange compared to sham exchange or supportive treatment for Guillain-Barré syndrome: four-week end points</NAME>
<DICH_OUTCOME CHI2="3.0430680593979402" CI_END="2.1502698179760658" CI_START="1.1945193804849095" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6026662069327378" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="47" I2="34.276856088598535" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.33249295903460835" LOG_CI_START="0.07719320035577774" LOG_EFFECT_SIZE="0.20484307969519303" METHOD="MH" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="0.2183767130253369" P_Q="1.0" P_Z="0.001659703970490174" Q="0.0" RANDOM="NO" SCALE="5.83" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="177" WEIGHT="100.0" Z="3.145205156185975">
<NAME>Walking with aid after 4 weeks</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.6805172124397885" CI_START="1.0550696388453455" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.6702938466846698" LOG_CI_START="0.023281125764642783" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="1" O_E="0.0" SE="0.38005847503304596" STUDY_ID="STD-Osterman-1984" TOTAL_1="18" TOTAL_2="20" VAR="0.14444444444444443" WEIGHT="12.277894168749837"/>
<DICH_DATA CI_END="2.387353473363077" CI_START="1.2066289341296477" EFFECT_SIZE="1.6972477064220184" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" LOG_CI_END="0.37791672573738144" LOG_CI_START="0.08157373518739887" LOG_EFFECT_SIZE="0.22974523046239018" MODIFIED="2012-02-11 10:17:19 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.17407333957052118" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.030301527549233973" WEIGHT="70.63199673189142"/>
<DICH_DATA CI_END="2.0335254398195612" CI_START="0.28904372980449783" EFFECT_SIZE="0.7666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.30824960988746997" LOG_CI_START="-0.5390364472916089" LOG_EFFECT_SIZE="-0.11539341870206953" ORDER="3" O_E="0.0" SE="0.4977000241206161" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="0.24770531400966184" WEIGHT="17.09010909935875"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8219348153221575" CI_END="1.95546916387427" CI_START="1.367931806851819" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6355269690780234" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="110" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.2912509718786188" LOG_CI_START="0.1360644477889645" LOG_EFFECT_SIZE="0.21365770983379165" METHOD="MH" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="0.43064049720849984" P_Q="1.0" P_Z="6.781023199339256E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="308" TOTAL_2="315" WEIGHT="100.0" Z="5.396878611078553">
<NAME>Improvement by 1 grade after 4 weeks</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.122729268507275" CI_START="0.520809490402555" EFFECT_SIZE="1.7857142857142858" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7869450564645077" LOG_CI_START="-0.28332111047690856" LOG_EFFECT_SIZE="0.2518119729937996" ORDER="4" O_E="0.0" SE="0.6286796443643577" STUDY_ID="STD-Greenwood-1984" TOTAL_1="14" TOTAL_2="15" VAR="0.3952380952380953" WEIGHT="2.6604784007434708"/>
<DICH_DATA CI_END="1.8185407310499224" CI_START="1.0364103967193499" EFFECT_SIZE="1.372863620509243" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="47" LOG_CI_END="0.259723032678123" LOG_CI_START="0.015531760947515719" LOG_EFFECT_SIZE="0.13762739681281938" MODIFIED="2012-02-07 06:08:05 +0000" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.1434391617808485" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" VAR="0.02057479313239243" WEIGHT="42.99322753605722"/>
<DICH_DATA CI_END="5.292035007488504" CI_START="1.270123183549364" EFFECT_SIZE="2.5925925925925926" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7236227084385163" LOG_CI_START="0.10384584327202284" LOG_EFFECT_SIZE="0.4137342758552695" MODIFIED="2012-02-07 06:08:05 +0000" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.36405999854376" STUDY_ID="STD-Osterman-1984" TOTAL_1="18" TOTAL_2="20" VAR="0.1325396825396825" WEIGHT="5.220938816496585"/>
<DICH_DATA CI_END="2.2127185817564414" CI_START="1.251551343359655" EFFECT_SIZE="1.6641306780040277" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="41" LOG_CI_END="0.3449261829458065" LOG_CI_START="0.09744867070844293" LOG_EFFECT_SIZE="0.22118742682712472" ORDER="7" O_E="0.0" SE="0.14536951572167003" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.021132296101152873" WEIGHT="37.31608887605569"/>
<DICH_DATA CI_END="3.451914586812209" CI_START="1.210850668897834" EFFECT_SIZE="2.0444444444444443" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.5380600411176033" LOG_CI_START="0.08309058602281995" LOG_EFFECT_SIZE="0.31057531357021156" ORDER="8" O_E="0.0" SE="0.2672513100578004" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="0.07142326272761056" WEIGHT="11.80926637064704"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.1018614531718507" CI_END="-0.633824969652077" CI_START="-1.1379333542983936" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8858791619752353" ESTIMABLE="YES" I2="3.283881459879224" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2017-01-09 16:33:37 +0000" MODIFIED_BY="Ruth Brassington" NO="3" NOTES="&lt;p&gt;By calling this outcome improvement and not changing the sign it looks as if the PE group have had significantly less improvement. I have adjusted the scale on the figure so that it is about right. This needs to be done for all the figures. The summary of findings table will need to be redone after this change.&lt;/p&gt;" NOTES_MODIFIED="2017-01-09 16:33:37 +0000" NOTES_MODIFIED_BY="Ruth Brassington" P_CHI2="0.37618549565406834" P_Q="1.0" P_Z="5.635866617086752E-12" Q="0.0" RANDOM="NO" SCALE="2.49" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="290" TOTAL_2="295" UNITS="" WEIGHT="100.0" Z="6.888563273329293">
<NAME>Mean disability grade improvement after 4 weeks</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5145466888755305" CI_START="-1.2545466888755303" EFFECT_SIZE="-0.37" ESTIMABLE="YES" MEAN_1="-0.64" MEAN_2="-0.27" ORDER="9" SD_1="1.35" SD_2="1.05" SE="0.45130762394244067" STUDY_ID="STD-Greenwood-1984" TOTAL_1="14" TOTAL_2="15" WEIGHT="8.119818623632513"/>
<CONT_DATA CI_END="-0.2558833391658867" CI_START="-1.1441166608341136" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.4" ORDER="10" SD_1="1.93" SD_2="1.6" SE="0.22659429680200704" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" WEIGHT="32.210222060993466"/>
<CONT_DATA CI_END="-0.5410954310808092" CI_START="-1.4789045689191909" EFFECT_SIZE="-1.01" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-0.29" ORDER="11" SD_1="1.93" SD_2="1.6" SE="0.23924142107602503" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" WEIGHT="28.894748698081685"/>
<CONT_DATA CI_END="-0.6456469911785245" CI_START="-1.5543530088214756" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="0.1" ORDER="12" SD_1="1.2" SD_2="1.0" SE="0.2318170192949228" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" WEIGHT="30.775210617292334"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.937927454720562" CI_END="2.79253609256481" CI_START="1.0581997731819373" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7190291038125143" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="21" I2="74.80450644820857" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.4459987949301493" LOG_CI_START="0.02456766410792271" LOG_EFFECT_SIZE="0.23528322951903605" METHOD="MH" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="4" P_CHI2="0.018893047101905758" P_Q="1.0" P_Z="0.0286347064640499" Q="0.0" RANDOM="NO" SCALE="120.86" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="177" WEIGHT="100.0" Z="2.1884793139219165">
<NAME>Walking without aid after 4 weeks</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="57.251558094143675" CI_START="1.0566319795352757" EFFECT_SIZE="7.777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7577873104439088" LOG_CI_START="0.023923750705955493" LOG_EFFECT_SIZE="0.8908555305749319" ORDER="13" O_E="0.0" SE="1.0184800377531154" STUDY_ID="STD-Osterman-1984" TOTAL_1="18" TOTAL_2="20" VAR="1.0373015873015872" WEIGHT="4.568475792884607"/>
<DICH_DATA CI_END="8.115692151336274" CI_START="1.1500319508542225" EFFECT_SIZE="3.055045871559633" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.9093255647891525" LOG_CI_START="0.06070990634223994" LOG_EFFECT_SIZE="0.4850177355656963" ORDER="14" O_E="0.0" SE="0.4984810384869741" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.24848334573105216" WEIGHT="23.892205472383893"/>
<DICH_DATA CI_END="1.6446381924909734" CI_START="0.4772263892515782" EFFECT_SIZE="0.8859259259259259" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.21607037141231" LOG_CI_START="-0.32127554909753814" LOG_EFFECT_SIZE="-0.052602588842614095" MODIFIED="2016-08-09 00:30:15 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.3156396536126897" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="0.09962839093273874" WEIGHT="71.5393187347315"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.03247681710754" CI_END="0.735623370035754" CI_START="0.38514144467906347" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5322772280261965" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="85" I2="43.12103539012872" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.1333444821034155" LOG_CI_START="-0.4143797448751935" LOG_EFFECT_SIZE="-0.2738621134893045" METHOD="MH" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="5" P_CHI2="0.13418209407104476" P_Q="1.0" P_Z="1.3351896764289778E-4" Q="0.0" RANDOM="NO" SCALE="202.55" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="308" TOTAL_2="315" WEIGHT="100.00000000000001" Z="3.819875654571844">
<NAME>Mechanically ventilated after 4 weeks</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.862458070743028" CI_START="0.09861884800149007" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2700865043197091" LOG_CI_START="-1.0060400749088978" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="16" O_E="0.0" SE="0.749603069567329" STUDY_ID="STD-Greenwood-1984" TOTAL_1="14" TOTAL_2="15" VAR="0.5619047619047619" WEIGHT="5.710243440903796"/>
<DICH_DATA CI_END="1.2030821157303204" CI_START="0.49406507203523453" EFFECT_SIZE="0.7709739633558341" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.08029527089052517" LOG_CI_START="-0.3062158475041" LOG_EFFECT_SIZE="-0.11296028830678746" ORDER="17" O_E="0.0" SE="0.2270385442058956" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" VAR="0.0515465005551324" WEIGHT="40.05228011622154"/>
<DICH_DATA CI_END="2.8080993372511047" CI_START="0.28137304343499053" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4484124670108019" LOG_CI_START="-0.5507175119055646" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="18" O_E="0.0" SE="0.5868938953886337" STUDY_ID="STD-Osterman-1984" TOTAL_1="18" TOTAL_2="20" VAR="0.3444444444444445" WEIGHT="5.602908037879288"/>
<DICH_DATA CI_END="0.5817356545865486" CI_START="0.17777168055842213" EFFECT_SIZE="0.32158377595364557" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="38" LOG_CI_END="-0.2352743174709161" LOG_CI_START="-0.7501374219753869" LOG_EFFECT_SIZE="-0.49270586972315156" ORDER="19" O_E="0.0" SE="0.302433136199397" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.09146580187140302" WEIGHT="44.53915724899235"/>
<DICH_DATA CI_END="2.747710364046198" CI_START="0.007753771896789141" EFFECT_SIZE="0.14596273291925466" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43897095184971113" LOG_CI_START="-2.110486979369938" LOG_EFFECT_SIZE="-0.8357580137601135" ORDER="20" O_E="0.0" SE="1.4975642088187144" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="2.242698559534822" WEIGHT="4.0954111560030455"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.06604189450082804" CI_END="2.756964584791028" CI_START="-12.935654153731413" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.0893447844701925" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2017-01-09 12:52:36 +0000" MODIFIED_BY="Sophie Maprayil" NO="6" P_CHI2="0.7971894489869629" P_Q="1.0" P_Z="0.2036256216283322" Q="0.0" RANDOM="NO" SCALE="20.629186490770028" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="75" UNITS="" WEIGHT="100.0" Z="1.2712897252746924">
<NAME>Duration of mechanical ventilation</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.205345955729292" CI_START="-17.405345955729295" EFFECT_SIZE="-3.6000000000000014" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="15.3" ORDER="21" SD_1="12.2" SD_2="6.1" SE="7.043673284113433" STUDY_ID="STD-Farkkila-1987" TOTAL_1="4" TOTAL_2="3" WEIGHT="32.30250979680936"/>
<CONT_DATA CI_END="3.736283284627241" CI_START="-15.336283284627235" EFFECT_SIZE="-5.799999999999997" ESTIMABLE="YES" MEAN_1="27.5" MEAN_2="33.3" ORDER="22" SD_1="29.3" SD_2="23.2" SE="4.865540060862457" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="53" TOTAL_2="72" WEIGHT="67.69749020319064"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="2">
<NAME>Plasma exchange compared to sham exchange or supportive treatment for Guillain-Barré syndrome: one-year end points</NAME>
<DICH_OUTCOME CHI2="1.2432517113604384" CI_END="1.4453402414983882" CI_START="1.0674488303640004" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.242105772575539" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="112" I2="0.0" I2_Q="100.0" ID="CMP-002.01" LOG_CI_END="0.15997009457459352" LOG_CI_START="0.0283470656893942" LOG_EFFECT_SIZE="0.09415858013199385" METHOD="MH" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="0.8709274767056931" P_Q="0.0" P_Z="0.005044451227883031" Q="1.2887287344044882E-31" RANDOM="NO" SCALE="4.04" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="205" WEIGHT="99.99999999999999" Z="2.8041814180571327">
<NAME>Full muscle strength recovery at 1 year</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4432891436261532" CI_START="0.8245628742402284" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.15935334488559" LOG_CI_START="-0.08377622310679056" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="23" O_E="0.0" SE="0.1428155117494959" STUDY_ID="STD-Farkkila-1987" TOTAL_1="13" TOTAL_2="13" VAR="0.0203962703962704" WEIGHT="9.974638286252512"/>
<DICH_DATA CI_END="3.4836416990053385" CI_START="0.32952848853578676" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.542033480392197" LOG_CI_START="-0.4821070336373106" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="24" O_E="0.0" SE="0.6015852075182384" STUDY_ID="STD-Greenwood-1984" TOTAL_1="14" TOTAL_2="15" VAR="0.36190476190476195" WEIGHT="3.5020673606905373"/>
<DICH_DATA CI_END="1.6016995564988612" CI_START="0.8769834002157572" EFFECT_SIZE="1.1851851851851851" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.20458105532401322" LOG_CI_START="-0.05700862700217594" LOG_EFFECT_SIZE="0.07378621416091864" ORDER="25" O_E="0.0" SE="0.15365907428821474" STUDY_ID="STD-Osterman-1984" TOTAL_1="18" TOTAL_2="20" VAR="0.023611111111111097" WEIGHT="12.885896350661142"/>
<DICH_DATA CI_END="1.5723695582295998" CI_START="0.9946830177405646" EFFECT_SIZE="1.2506035731530663" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="57" LOG_CI_END="0.19655462709610386" LOG_CI_START="-0.0023152967205053504" LOG_EFFECT_SIZE="0.09711966518779927" ORDER="26" O_E="0.0" SE="0.1168171776718757" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.013646252999222576" WEIGHT="51.21688237395608"/>
<DICH_DATA CI_END="1.8546854976524472" CI_START="0.9816761099113466" EFFECT_SIZE="1.3493333333333333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="25" LOG_CI_END="0.26827027609982285" LOG_CI_START="-0.008031777875662375" LOG_EFFECT_SIZE="0.13011924911208025" ORDER="27" O_E="0.0" SE="0.16230119422242548" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="0.026341677646025477" WEIGHT="22.420515628439713"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.392762662630549" CI_END="1.6497086770629492" CI_START="0.4505785524620863" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.862162019399583" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.21740725868998642" LOG_CI_START="-0.346229484536398" LOG_EFFECT_SIZE="-0.0644111129232058" METHOD="MH" MODIFIED="2017-01-09 12:52:48 +0000" MODIFIED_BY="Sophie Maprayil" NO="2" P_CHI2="0.9251033348998755" P_Q="1.0" P_Z="0.6541818005006818" Q="0.0" RANDOM="NO" SCALE="110.44841739755125" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="321" TOTAL_2="328" WEIGHT="100.00000000000001" Z="0.44796036827187535">
<NAME>Deaths</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.43689862203422" CI_START="0.20579414842785088" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.288626969500306" LOG_CI_START="-0.6865669781723437" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="28" O_E="0.0" SE="1.1602387022306428" STUDY_ID="STD-Farkkila-1987" TOTAL_1="13" TOTAL_2="13" VAR="1.3461538461538463" WEIGHT="5.490479506868861"/>
<DICH_DATA CI_END="2.4818757211437776" CI_START="0.11563423320250196" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.39478003059832545" LOG_CI_START="-0.9369135751714015" LOG_EFFECT_SIZE="-0.27106677228653797" ORDER="29" O_E="0.0" SE="0.7822434160188003" STUDY_ID="STD-Greenwood-1984" TOTAL_1="14" TOTAL_2="15" VAR="0.611904761904762" WEIGHT="21.20461050928664"/>
<DICH_DATA CI_END="3.3079574189382988" CI_START="0.17284355005968097" EFFECT_SIZE="0.7561475409836066" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5195599105421923" LOG_CI_START="-0.7623468222294928" LOG_EFFECT_SIZE="-0.12139345584365023" ORDER="30" O_E="0.0" SE="0.7529983603707546" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" VAR="0.5670065307210448" WEIGHT="21.872277545730647"/>
<DICH_DATA CI_END="16.49457919273206" CI_START="0.07484688677468962" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.217341240366019" LOG_CI_START="-1.125826259244669" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="31" O_E="0.0" SE="1.3763881881375053" STUDY_ID="STD-Osterman-1984" TOTAL_1="18" TOTAL_2="20" VAR="1.8944444444444444" WEIGHT="5.201506901244184"/>
<DICH_DATA CI_END="2.8065114734200916" CI_START="0.36950995195468433" EFFECT_SIZE="1.018348623853211" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.44816682201724434" LOG_CI_START="-0.4323738603251769" LOG_EFFECT_SIZE="0.007896480846033753" ORDER="32" O_E="0.0" SE="0.5172339555546128" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.26753096477867117" WEIGHT="38.08396239764492"/>
<DICH_DATA CI_END="8.146451329441069" CI_START="0.014238658560838814" EFFECT_SIZE="0.34057971014492755" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9109684671857768" LOG_CI_START="-1.846530924116815" LOG_EFFECT_SIZE="-0.467781228465519" ORDER="33" O_E="0.0" SE="1.6197687922932713" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="2.623650940487203" WEIGHT="8.147163139224762"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5077589394086797" CI_END="0.9551773610886369" CI_START="0.4439858456104289" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6512182647706347" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.01991597942115005" LOG_CI_START="-0.35263087509094587" LOG_EFFECT_SIZE="-0.18627342725604795" METHOD="MH" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="3" P_CHI2="0.6432470717412582" P_Q="1.0" P_Z="0.028191805658243394" Q="0.0" RANDOM="NO" SCALE="125.9" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="321" TOTAL_2="328" WEIGHT="100.0" Z="2.1946069349478714">
<NAME>Severe motor sequelae</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="34" O_E="0.0" SE="0.0" STUDY_ID="STD-Farkkila-1987" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.2758346631279895" CI_START="0.05439704127274793" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7222911769394742" LOG_CI_START="-1.26442472151255" LOG_EFFECT_SIZE="-0.27106677228653797" ORDER="35" O_E="0.0" SE="1.1670067531530235" STUDY_ID="STD-Greenwood-1984" TOTAL_1="14" TOTAL_2="15" VAR="1.361904761904762" WEIGHT="3.514378326715365"/>
<DICH_DATA CI_END="0.9833736134144655" CI_START="0.38602227938988976" EFFECT_SIZE="0.6161202185792349" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="36" LOG_CI_END="-0.007281449190292855" LOG_CI_START="-0.4133876291705698" LOG_EFFECT_SIZE="-0.21033453918043135" ORDER="36" O_E="0.0" SE="0.2385487803784266" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" VAR="0.056905520620034816" WEIGHT="65.25063246604702"/>
<DICH_DATA CI_END="2.2610071290709564" CI_START="0.03412660351003211" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3543019317002011" LOG_CI_START="-1.4669069332347755" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="37" O_E="0.0" SE="1.0697871023920809" STUDY_ID="STD-Osterman-1984" TOTAL_1="18" TOTAL_2="20" VAR="1.1444444444444444" WEIGHT="6.896637167463987"/>
<DICH_DATA CI_END="2.250209105822" CI_START="0.46086113375890037" EFFECT_SIZE="1.018348623853211" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.35222287779357203" LOG_CI_START="-0.3364299161015046" LOG_EFFECT_SIZE="0.007896480846033753" ORDER="38" O_E="0.0" SE="0.4045180600202756" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.16363486088256732" WEIGHT="19.83741051919155"/>
<DICH_DATA CI_END="4.141664288921303" CI_START="0.010082428490924583" EFFECT_SIZE="0.20434782608695654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.61717489335565" LOG_CI_START="-1.9964348495194006" LOG_EFFECT_SIZE="-0.6896299780818754" ORDER="39" O_E="0.0" SE="1.5352473005416867" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="2.356984273820536" WEIGHT="4.500941520582082"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5175734348359455" CI_END="7.927067783966321" CI_START="1.0531928426536568" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8894170784612787" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.8991125718400087" LOG_CI_START="0.02250789904152768" LOG_EFFECT_SIZE="0.46081023544076816" METHOD="MH" MODIFIED="2017-01-09 12:53:05 +0000" MODIFIED_BY="Sophie Maprayil" NO="4" P_CHI2="0.6414918860891968" P_Q="1.0" P_Z="0.039339981443002055" Q="0.0" RANDOM="NO" SCALE="251.22534961537306" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="321" TOTAL_2="328" WEIGHT="100.0" Z="2.0606129380716975">
<NAME>Relapses during follow-up period</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40" O_E="0.0" SE="0.0" STUDY_ID="STD-Farkkila-1987" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.539663588267699" CI_START="0.07387284654863233" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1914416127055374" LOG_CI_START="-1.1315151659506513" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="41" O_E="0.0" SE="1.3645163106041502" STUDY_ID="STD-Greenwood-1984" TOTAL_1="14" TOTAL_2="15" VAR="1.861904761904762" WEIGHT="19.63276699489928"/>
<DICH_DATA CI_END="7.04319200279068" CI_START="0.14431817682386944" EFFECT_SIZE="1.0081967213114753" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8477695277528187" LOG_CI_START="-0.8406789662235193" LOG_EFFECT_SIZE="0.0035452807646496587" ORDER="42" O_E="0.0" SE="0.9918030033165415" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" VAR="0.9836731973877115" WEIGHT="40.501883164987554"/>
<DICH_DATA CI_END="76.5975747998518" CI_START="0.1435353516416592" EFFECT_SIZE="3.3157894736842106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8842150194013312" LOG_CI_START="-0.8430411223998254" LOG_EFFECT_SIZE="0.5205869485007527" ORDER="43" O_E="0.0" SE="1.6020037578296284" STUDY_ID="STD-Osterman-1984" TOTAL_1="18" TOTAL_2="20" VAR="2.5664160401002505" WEIGHT="9.658620191240628"/>
<DICH_DATA CI_END="49.918045485325905" CI_START="0.7478902818883172" EFFECT_SIZE="6.110091743119266" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6982575724364792" LOG_CI_START="-0.12616210997712443" LOG_EFFECT_SIZE="0.7860477312296774" ORDER="44" O_E="0.0" SE="1.0716731524728293" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="1.1484833457310524" WEIGHT="20.14908326976514"/>
<DICH_DATA CI_END="134.63780783826363" CI_START="0.37993482294266784" EFFECT_SIZE="7.1521739130434785" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1291670318782248" LOG_CI_START="-0.4202908993414244" LOG_EFFECT_SIZE="0.8544380662684002" ORDER="45" O_E="0.0" SE="1.4975642088187144" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="2.242698559534822" WEIGHT="10.05764637910739"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="3">
<NAME>Plasma exchange compared to sham exchange or supportive treatment for Guillain-Barré syndrome: complications during hospital stay</NAME>
<DICH_OUTCOME CHI2="3.276416703784917" CI_END="1.126966682362594" CI_START="0.7300521754723976" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9070526325102211" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="104" I2="38.957703466424164" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.051911076755987655" LOG_CI_START="-0.13664610055075394" LOG_EFFECT_SIZE="-0.042367511897383164" METHOD="MH" MODIFIED="2017-01-18 15:41:32 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="0.19432807097364202" P_Q="1.0" P_Z="0.37843632985506437" Q="0.0" RANDOM="NO" SCALE="22.531421177677917" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="280" WEIGHT="100.0" Z="0.8807810831656347">
<NAME>Severe infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4758633489388355" CI_START="0.7235893139884908" EFFECT_SIZE="1.0334016393442622" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="40" LOG_CI_END="0.16904614776534058" LOG_CI_START="-0.140507855452495" LOG_EFFECT_SIZE="0.014269146156422772" ORDER="46" O_E="0.0" SE="0.18183355380718544" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" VAR="0.033063441290150604" WEIGHT="38.58663136673335"/>
<DICH_DATA CI_END="1.196935870451216" CI_START="0.690694557669908" EFFECT_SIZE="0.9092398427260813" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="56" LOG_CI_END="0.07807088235690755" LOG_CI_START="-0.1607139660052032" LOG_EFFECT_SIZE="-0.04132154182414781" ORDER="47" O_E="0.0" SE="0.14026340193196635" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.01967382192152834" WEIGHT="53.749567321462735"/>
<DICH_DATA CI_END="1.1384692056537622" CI_START="0.0573653126944311" EFFECT_SIZE="0.25555555555555554" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05632128791952629" LOG_CI_START="-1.2413506347629901" LOG_EFFECT_SIZE="-0.592514673421732" ORDER="48" O_E="0.0" SE="0.7622589109633257" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="0.5810386473429952" WEIGHT="7.663801311803913"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.511723907261531" CI_END="1.2198334414427694" CI_START="0.6353403742303938" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8803462018916185" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="60" I2="63.713712195107234" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.08630053526449383" LOG_CI_START="-0.19699354550161913" LOG_EFFECT_SIZE="-0.05534650511856264" METHOD="MH" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="0.06355425531518" P_Q="1.0" P_Z="0.4437791322990785" Q="0.0" RANDOM="NO" SCALE="10.55192043033702" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="280" WEIGHT="100.0" Z="0.7658272026664974">
<NAME>Blood pressure instability</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.285170244681252" CI_START="0.8594689274973025" EFFECT_SIZE="1.680327868852459" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" LOG_CI_END="0.5165578805654608" LOG_CI_START="-0.06576981980344873" LOG_EFFECT_SIZE="0.22539403038100606" ORDER="49" O_E="0.0" SE="0.3420621737653038" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" VAR="0.1170065307210449" WEIGHT="20.08592684129631"/>
<DICH_DATA CI_END="1.0679185455160567" CI_START="0.47582900661142874" EFFECT_SIZE="0.7128440366972477" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="40" LOG_CI_END="0.02853812855211169" LOG_CI_START="-0.3225490868315304" LOG_EFFECT_SIZE="-0.14700547913970935" ORDER="50" O_E="0.0" SE="0.20623036822609614" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.0425309647786712" WEIGHT="66.61632840248608"/>
<DICH_DATA CI_END="1.5785643313156286" CI_START="0.1654887056034725" EFFECT_SIZE="0.5111111111111111" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.19826228541486204" LOG_CI_START="-0.7812316409303638" LOG_EFFECT_SIZE="-0.29148467775775083" ORDER="51" O_E="0.0" SE="0.5753595809083178" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="0.3310386473429952" WEIGHT="13.297744756217607"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.675791920254395" CI_END="0.9974708124476707" CI_START="0.5564657482090124" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7450223768218942" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="79" I2="45.589956031526846" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.0010998035894595245" LOG_CI_START="-0.2545615623654253" LOG_EFFECT_SIZE="-0.12783068297744243" METHOD="MH" MODIFIED="2011-07-15 17:53:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.15915201629411835" P_Q="1.0" P_Z="0.048044675148459406" Q="0.0" RANDOM="NO" SCALE="5.28" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="280" WEIGHT="100.0" Z="1.9769730626417639">
<NAME>Cardiac arrhythmias</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.709055899815549" CI_START="0.6432813673895046" EFFECT_SIZE="1.0485245901639344" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.23275626786082" LOG_CI_START="-0.19159902773395995" LOG_EFFECT_SIZE="0.020578620063430048" ORDER="52" O_E="0.0" SE="0.24926840122496485" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" VAR="0.062134735849250056" WEIGHT="31.759358506833195"/>
<DICH_DATA CI_END="0.8464319507516698" CI_START="0.3876555148525159" EFFECT_SIZE="0.5728211009174312" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="48" LOG_CI_END="-0.07240795143690669" LOG_CI_START="-0.41155403330422546" LOG_EFFECT_SIZE="-0.24198099237056608" ORDER="53" O_E="0.0" SE="0.19921608728904364" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="0.03968704943475585" WEIGHT="60.67126096631753"/>
<DICH_DATA CI_END="2.593626727253102" CI_START="0.2797825800754157" EFFECT_SIZE="0.8518518518518519" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.41390747292036006" LOG_CI_START="-0.5531793292031489" LOG_EFFECT_SIZE="-0.06963592814139442" ORDER="54" O_E="0.0" SE="0.568071574724226" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="0.3227053140096619" WEIGHT="7.569380526849274"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5350879075680218" CI_END="3.995896948590933" CI_START="0.2562908713351923" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0119841454884588" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.6016142795450856" LOG_CI_START="-0.5912668624047428" LOG_EFFECT_SIZE="0.005173708570171354" METHOD="MH" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="4" P_CHI2="0.4644756972868326" P_Q="1.0" P_Z="0.9864355554181502" Q="0.0" RANDOM="NO" SCALE="39.46" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="280" WEIGHT="100.0" Z="0.017001329147457615">
<NAME>Pulmonary embolus</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.95222438022603" CI_START="0.11430532177146352" EFFECT_SIZE="0.6721311475409836" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5968415928811197" LOG_CI_START="-0.941933549463183" LOG_EFFECT_SIZE="-0.17254597829103155" ORDER="55" O_E="0.0" SE="0.9038841356728443" STUDY_ID="STD-McKhann-1985" TOTAL_1="122" TOTAL_2="123" VAR="0.8170065307210448" WEIGHT="75.09442760550245"/>
<DICH_DATA CI_END="22.13569704027699" CI_START="0.18739575588097251" EFFECT_SIZE="2.036697247706422" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3450932022118471" LOG_CI_START="-0.7272402491918173" LOG_EFFECT_SIZE="0.3089264765100149" ORDER="56" O_E="0.0" SE="1.2172989275705395" STUDY_ID="STD-Rapha_x00eb_l-1987" TOTAL_1="109" TOTAL_2="111" VAR="1.4818166790643856" WEIGHT="24.905572394497554"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="57" O_E="0.0" SE="0.0" STUDY_ID="STD-Rapha_x00eb_l-1997a" TOTAL_1="45" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-01-23 17:01:37 +0000" MODIFIED_BY="Ruth Brassington">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-01-23 17:01:36 +0000" MODIFIED_BY="Ruth Brassington" NO="1" NOTES="&lt;p&gt;Djillali Please check Richard&lt;/p&gt;" NOTES_MODIFIED="2017-01-23 17:01:36 +0000" NOTES_MODIFIED_BY="Ruth Brassington" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAr4AAAQ8CAYAAAB0L52cAACAAElEQVR42uy9D0Rl2//H/SVJkkRy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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-01-09 16:09:27 +0000" MODIFIED_BY="Ruth Brassington" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Green (+) = low risk of bias, yellow (?) = unclear risk of bias, red (-) = high risk of bias.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASwAAAIKCAIAAAAWAuWUAAAXJUlEQVR42u3dv64dSbXH8SMhIQIH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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-01-23 17:01:37 +0000" MODIFIED_BY="Ruth Brassington" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Plasma exchange compared to sham exchange or supportive treatment for Guillain-Barré syndrome, outcome: 1.2 Improved or not by 1 grade after 4 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAADQCAMAAACN8A91AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2017-01-23 17:01:37 +0000" MODIFIED_BY="Ruth Brassington" NO="4" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Plasma exchange compared to sham exchange or supportive treatment for Guillain-Barré syndrome, outcome: 1.5 On or not on a ventilator after 4 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAADQCAMAAACN8A91AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2017-01-23 17:01:37 +0000" MODIFIED_BY="Ruth Brassington" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Plasma exchange compared to sham exchange or supportive treatment for Guillain-Barré syndrome, outcome: 2.1 Full muscle strength recovered or not at 1 year.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAADQCAMAAACN8A91AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2017-01-23 17:01:37 +0000" MODIFIED_BY="Ruth Brassington" NO="6" REF_ID="CMP-002.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Plasma exchange compared to sham exchange or supportive treatment for Guillain-Barré syndrome, outcome: 2.3 Having or not severe motor sequelae after 1 year.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAADgCAMAAACJigjYAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-05-09 09:44:28 +0100" MODIFIED_BY="Ruth  Brassington">
<APPENDIX ID="APP-01" MODIFIED="2016-01-18 15:39:05 +0000" MODIFIED_BY="Angela A Gunn" NO="1">
<TITLE MODIFIED="2016-01-18 15:39:05 +0000" MODIFIED_BY="Angela A Gunn">Cochrane Neuromuscular Specialised Register (CRS) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-04-14 13:43:21 +0100" MODIFIED_BY="Angela A Gunn">
<P>#1 "guillain barre" [REFERENCE] [STANDARD]<BR/>#2 MeSH DESCRIPTOR Polyradiculoneuropathy [REFERENCE] [STANDARD]<BR/>#3 MeSH DESCRIPTOR Polyneuropathies [REFERENCE] [STANDARD]<BR/>#4 "acute polyradiculoneuritis" or "acute polyneuritis" [REFERENCE] [STANDARD]<BR/>#5 (inflammatory NEAR5 neuropathy) or (inflammatory NEAR5 neuropathies) [REFERENCE] [STANDARD]<BR/>#6 (inflammatory NEAR5 polyneuropathy) or (inflammatory NEAR5 polyneuropathies) [REFERENCE] [STANDARD]<BR/>#7 #1 or #2 or #3 or #4 or #5 or #6 [REFERENCE] [STANDARD]<BR/>#8 "plasma exchange" or plasmapheresis [REFERENCE] [STANDARD]<BR/>#9 #7 and #8 [REFERENCE] [STANDARD]<BR/>#10 (#7 and #8) AND (INREGISTER) [REFERENCE] [STANDARD]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-01-18 15:38:17 +0000" MODIFIED_BY="Angela A Gunn" NO="2">
<TITLE MODIFIED="2016-01-18 15:38:17 +0000" MODIFIED_BY="Angela A Gunn">The Cochrane Central Register of Controlled Trials (CRSO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 15:37:44 +0000" MODIFIED_BY="Angela A Gunn">
<P>#1("guillain barre syndrome*"):TI,AB,KY<BR/>#2MESH DESCRIPTOR Polyradiculoneuropathy<BR/>#3MESH DESCRIPTOR Polyneuropathies<BR/>#4("acute polyradiculoneuritis" or "acute polyneuritis"):TI,AB,KY<BR/>#5(inflammatory NEAR polyneuropath*):TI,AB,KY<BR/>#6(inflammatory NEAR neuropath*):TI,AB,KY<BR/>#7#1 OR #2 OR #3 OR #4 OR #5 or #6<BR/>#8"plasma exchange" or plasmapheresis<BR/>#9#7 AND #8<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-01-18 14:49:58 +0000" MODIFIED_BY="Angela A Gunn" NO="3">
<TITLE MODIFIED="2011-09-15 15:02:47 +0100" MODIFIED_BY="Angela A Gunn">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 14:49:58 +0000" MODIFIED_BY="Angela A Gunn">
<P>Database: Ovid MEDLINE(R) &lt;1946 to January Week 1 2016&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (403073)<BR/>2 controlled clinical trial.pt. (89915)<BR/>3 randomized.ab. (300387)<BR/>4 placebo.ab. (154014)<BR/>5 drug therapy.fs. (1808615)<BR/>6 randomly.ab. (212904)<BR/>7 trial.ab. (309257)<BR/>8 groups.ab. (1350141)<BR/>9 or/1-8 (3426105)<BR/>10 exp animals/ not humans.sh. (4171020)<BR/>11 9 not 10 (2916990)<BR/>12 guillain barre syndrome.tw. or Guillain-Barre Syndrome/ (7019)<BR/>13 polyradiculoneuropathy/ or polyneuropathies/ (8127)<BR/>14 (acute polyradiculoneuritis or acute polyneuritis).mp. (176)<BR/>15 (inflammatory adj5 neuropath$3).tw. (1919)<BR/>16 (inflammatory adj5 polyneuropath$3).tw. (1517)<BR/>17 or/12-16 (15117)<BR/>18 Plasma exchange.tw. or Plasma Exchange/ (7406)<BR/>19 plasmapheresis.tw. or plasmapheresis/ (10524)<BR/>20 18 or 19 (16647)<BR/>21 11 and 17 and 20 (339)<BR/>22 remove duplicates from 21 (331)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-01-18 15:20:10 +0000" MODIFIED_BY="Angela A Gunn" NO="4">
<TITLE MODIFIED="2010-04-19 14:56:55 +0100" MODIFIED_BY="Angela Gunn">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 15:20:10 +0000" MODIFIED_BY="Angela A Gunn">
<P>Database: Embase &lt;1980 to 2016 Week 03&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 crossover-procedure/ (45572)<BR/>2 double-blind procedure/ (125253)<BR/>3 randomized controlled trial/ (390064)<BR/>4 single-blind procedure/ (21312)<BR/>5 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$ or allocat$ or volunteer$).tw. (1539078)<BR/>6 or/1-5 (1621877)<BR/>7 exp animals/ (20581748)<BR/>8 exp humans/ (16523153)<BR/>9 7 not (7 and 8) (4058595)<BR/>10 6 not 9 (1465076)<BR/>11 limit 10 to embase (1203331)<BR/>12 guillain barre syndrome.tw. or Guillain Barre Syndrome/ (12977)<BR/>13 (acute polyradiculoneuritis or acute polyneuritis).mp. (188)<BR/>14 Polyneuropathies/ or Polyradiculoneuropathy/ (9902)<BR/>15 (inflammatory adj5 neuropath$3).tw. (2986)<BR/>16 (inflammatory adj5 polyneuropath$3).tw. (2377)<BR/>17 or/12-16 (24838)<BR/>18 Plasmapheresis/ or plasmapheresis.tw. (31307)<BR/>19 (plasma adj3 exchange).mp. (9945)<BR/>20 or/18-19 (33019)<BR/>21 11 and 17 and 20 (216)<BR/>22 remove duplicates from 21 (216)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-01-19 13:06:14 +0000" MODIFIED_BY="Angela A Gunn" NO="5">
<TITLE MODIFIED="2016-01-19 13:05:19 +0000" MODIFIED_BY="Angela A Gunn">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-19 13:06:14 +0000" MODIFIED_BY="Angela A Gunn">
<P>Advanced search</P>
<P>Condition: Guillain Barre</P>
<P>Intervention: plasma exchange</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-05-09 09:44:28 +0100" MODIFIED_BY="Ruth  Brassington" NO="6">
<TITLE MODIFIED="2016-05-09 09:44:28 +0100" MODIFIED_BY="Ruth  Brassington">WHO International Clinical Trials Registry Platform search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-19 13:13:39 +0000" MODIFIED_BY="Angela A Gunn">
<P>Basic search</P>
<P>guillain barre AND plasma Exchange</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 - studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in previous version of the review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;38 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;112 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;112 records after duplicates removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;148 records identified through database searching&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of additional records identified through other sources:&lt;/p&gt;&lt;p&gt;3 trials found in trials registry searches&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;74 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;20 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;Some papers excluded for more than one reason&lt;/p&gt;&lt;p&gt;2 were reviews&lt;/p&gt;&lt;p&gt;2 were commentaries&lt;/p&gt;&lt;p&gt;2 concerned chronic inflammatory demyelinating polyradiculoneuropathy not GBS&lt;/p&gt;&lt;p&gt;11 concerned corticosteroids&lt;/p&gt;&lt;p&gt;10 concerned IVIg&lt;/p&gt;&lt;p&gt;3 concerned prognostic factors&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>